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We work in the dark- we do what we can- we give what we have.  
Our doubt is our passion, and our passion is our task.  
The rest is madness of art. 
Henry James 
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ABSTRACT 
 
BACKGROUND: Hypospadias is a common inborn error of the male urethra that involves an abnormally 
placed urethral opening. Its complex etiology is largely elusive to date. Twin and familial studies highlight a 
genetic background in hypospadias. Environmental factors have also been identified, particularly the 
exposure to endocrine disrupters. For most of the cases, pedigree analyses indicate a heterogeneous, 
complex pattern of inheritance, with several genetic and environmental factors interacting, yielding high 
heritability indices. Hypospadias is therefore said to be a complex genetic disorder. 
 
HYPOTHESIS: As an inborn error of development, hypospadias may be induced by disturbances in the 
pathways of urethral development, which comprise genetic programming, cell differentiation, hormonal 
signaling, enzyme activity, and tissue remodeling; and follows an orderly sequence. We proposed that gene 
variants in FGF8, FGF10, FGFR2 and BMP7, important genes in the early urethral development; in FKBP52, 
an androgen receptor co-chaperone; in the estrogen receptor (ESR) genes 1 and 2; and ATF3, an estrogen 
responsive gene; may influence the risk to hypospadias. 
 
STRATEGY: Using a candidate gene strategy, we performed comprehensive analysis of these genes in DNA 
from boys with hypospadias and controls, including sequence analysis, genotyping and association studies; 
and complementary expression analysis in human tissues.  
 
RESULTS: Our results indicate that gene variants in the sequence of FGF8, FGFR2, two androgen-regulated 
developmental genes; and of ESR2 and ATF3, two estrogen related genes, are associated with hypospadias. 
We have shown that the last two are expressed in the human developing male urethra.  
 
DISCUSSION: The molecular mechanisms involved in the development of external genitalia during fetal life 
seem to depend on a complex balance between early morphogenetic cell-cell interactions; and between 
sex steroid hormones. These balances can be disturbed by the exposure to environmental endocrine 
disruptors. Ethnical differences in the response to such exposures denote that genetic factors also play an 
important role. The involvement of sequence variants in FGFR2, FGF8, ESR2 and ATF3, hormonal responsive 
genes, in hypospadias is reported in this thesis, increasing the understanding on the complex etiology of 
hypospadias. Further genetic analysis and gene-environment studies are encouraged. 
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LIST OF ABBREVIATIONS 
 
 
ATF3 activating transcription factor 3 
AR androgen receptor 
bp base pair 
BMP bone morphogenic protein 
cM centimorgan 
ESR1 estrogen receptor alfa 
ESR2 estrogen receptor beta 
FGF fibroblast growth factor 
FKBP4 gene coding for FKBP52 
FKBP52 FK506 binding protein 4, FKBP4 
FSH follicle stimulating hormone 
GT genital tubercle 
HOXA homeobox A cluster 
HOXD homeobox D cluster 
kb kilobase 
LD linkage disequilibrium 
LH luteinizing hormone 
Mb megabase 
SNP single nucleotide polymorphism 
SOX9 SRY box 9 
SRD5A2 5-alfa-reductase 
SRY sex determining region on Y chromosome 
SSR simple sequence repeat 
STRP short tandem repeat polymorphism 
TNF-beta transforming factor beta 
UPE urethral plate epithelium 
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BACKGROUND 
 
The knowledge of normal (…) processes and their genetic control has permitted an understanding of the 
abnormal and, reciprocally, understanding of the abnormal has increased our understanding of the normal.  
Epstein, 1978 
 
This thesis work focused on the genetics of hypospadias, a common inborn error of the genital 
development of still elusive etiology. The incidence of disorders of the genital development in humans, 
manifested as hypospadias, micropenis, cryptorchidism, and ambiguous genitalia, is as high as one in every 
hundred newborn babies (Vilain E, 2002) and are among the leading categories of structural birth defects in 
man (March of Dimes Perinatal Data Centre, 2000). Despite common, their causes are largely unknown. 
Studies of human birth defects and developmental disorders may provide a window through which we can 
understand normal morphogenesis at the molecular level (Donnai D and Read AP, 2001). This thesis aimed 
to add more knowledge to the etiology of one of these common disorders.  
 
HYPOSPADIAS: AN INBORN ERROR OF THE URETHRAL DEVELOPMENT 
 
From the Greek Hypo - meaning under - and spadon -meaning a fissure  
 
Hypospadias is a common inborn error of the male genital development. It results from an arrest in the 
normal development of the urethral, foreskin and ventral aspect of the penis during the gestational weeks 
8-16. As consequence, the foreskin in the ventral aspect of the penis and the spongiosum are malformed, 
with misplacement of the urethral opening, ventrally and proximally from the tip of the glans penis (Baskin 
LS, 2000).  
 
The site of failure of urethral fold fusion will dictate the position of the abnormal urethra meatus, as a 
continuum along the urethral shaft, from perineal positions proximally, to more distal openings along the 
penis (Figure 1). The majority of cases are mild, with an aberrant urethral meatus at the subcoronal margin, 
corona, or on the glans penis. The urethral opening in moderate and severe cases of is located more 
proximally on the penile shaft, scrotum, or perineum. More severe forms of hypospadias tend to associate 
with penile curvature as well as penile–scrotal skin transposition and intersex conditions (Baskin LS, 2000; 
Baskin LS et al, 2004). Surgery is performed to achieve normal urination, to correct the penis deformity, and 
to ensure normal sexual function.  
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Figure 1: Hypospadias. The anatomical location of the misplaced urethral meatus determines the severity of this 
inborn error of development. 
 
EPIDEMIOLOGICAL ASPECTS OF HYPOSPADIAS 
 
Hypospadias is a common disorder with an incidence up to 1 in every 250 live male births in western 
societies (Table 1). It usually occurs sporadically and as an isolated feature (non-syndromic). Less 
commonly, hypospadias may be associated with other conditions (syndromic), particularly with other 
genital anomalies such as undescended testis, bifid scrotum, and cryptorchidism (Erickson, JD 2004; Källén 
B and Winberg H, 1982; Paulozzi L, 1999). In up to 70 % of the cases, no cause is identified. 
 
Furthermore, the incidence of hypospadias worldwide seems to have been increasing in the past decades. 
In the US, two surveillance studies reported that the incidence had increased from about 1 in 500 total 
births in the 1970s to 1 in 250 total births in the 1990s (Paulozzi L et al, 1997).  
 
ETHNICITY INCIDENCE PHENOTYPE AUTHOR 
Sweden 1.53/1000 
75% Mild  
2.5% Moderate   
12. 5% Severe 
Källén, 1998 
UK 1.98/1000 
85% Mild  
14% Moderate   
1% Severe 
Roberts & Lloyd, 
1973 
France 2.98/1000 
69% Mild  
25% Moderate   
6% Severe 
Stoll 1990 
Latin America 0.76/1000 
72% Mild  
18,5% Moderate   
9.5% Severe 
Monteneole, 1981 
US 4/1000 
64.1% Mild 
21.9% Moderate to severe 
Paulozzi, 1997 
 
Table 1. The incidences of hypospadias in five reports worldwide range from 0.76 to 4 in 1000 male births. Mild 
hypospadias is the most frequent form in the five studies. The studies were conducted from 1973 to 1998.  
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EMBRYOLOGY OF HYPOSPADIAS 
 
As an inborn error of development, knowledge of the normal sexual differentiation and, especially, of the 
male genital and urethral development, may elucidate some of the causes of hypospadias.  
 
The complex processes of sex determination and differentiation, occurs on three levels (Figure 2): 
 
I. The chromosomal sex, determined at fertilization, when the 23 chromosomes from the egg 
combine with the 23 chromosomes from the sperm to produce a zygote, which then has 46 
chromosomes. Two of these chromosomes, X and Y, determine sex. The offspring always inherits an 
X chromosome from the mother. If the father also gives an X chromosome, the offspring will be 
female or XX. If the father gives a Y chromosome, then the offspring is male or XY.  
 
II. The gonadal sex, according to which gonad is formed: one of two organs can develop from the 
bipotential gonad: a testis or an ovary. In males, the sex-determining factor (SRY), expressed from 
the Y chromosome, causes the indifferent gonads to develop into testis. Here, testicular cords are 
formed and contain germ cells and Sertoli cells, while mesenchymal cells migrate into the 
interstitial space between the cords, giving rise to fetal Leydig cells. The testicular Leydig cells and 
Sertoli cells produce, respectively, testosterone and anti-Müllerian hormone (AMH or Müllerian 
inhibiting substance- MIS), two essential hormones for the correct differentiation of both primary 
and secondary sex characteristics. In the absence of SRY, the bipotential gonad develops into an 
ovary.  
 
III. The phenotypic sex: The development of secondary sex characteristics, including the external 
genitalia and the male or female ductal systems, depends on whether the gonad develops as a 
testis or an ovary. In males, the presence of AMH triggers the regression of the Müllerian duct, the 
anlagen of the female urogenital tract; while testosterone, maintains the Wolffian ducts. 
Furthermore, testosterone, in some tissues after its reduction to dihydrotestosterone (DHT), 
stimulates differentiation and growth of the prostate, seminal vesicles, and other parts of the male 
urogenital tract, including the masculinization of the external genitalia (Reviewed by Hughes IA, 
2001). It must be emphasized that, despite considered as default, the ovarian and female 
pathways, still not very well understood, are likely to be active genetic pathways (Brennan J et al, 
2004). 
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Figure 2. Steps in sex determination and differentiation. The proper sex development is dependent on several steps: 
The definition of the chromosomal sex; the formation of the gonads; and the apparent, or phenotypic, gonad. 
Disturbances at any of these complex levels can compromise the sexual differentiation of the new being (Adapted 
from Hughes IA, 2001). 
 
Disturbances of male sex differentiation lead to a variety of undervirilization phenotypes, ranging from 
males with hypospadias, individuals with ambiguous genitalia, to complete male pseudo-hermaphrodites. 
These phenotypes may be either due to insensitivity of the target cells to androgens; or to impaired 
testicular androgen action or production, as a result of a steroidogenic enzyme defect, such as 17ß-
hydroxysteroid dehydrogenase type II, or reduced sensitivity of the Leydig cells to luteinizing hormone (LH), 
a pituitary secreted hormone that stimulates de production of testosterone (Reviewed by Hughes IA, 2001). 
 
Recently, a number of other regulatory factors were described, which affect sexual development (Drews U, 
2000; Wilhelm D, 2007; Zarkower D, 2001; Parma P et al, 2006); furthermore, the importance of estrogens 
and their receptors in male sex development has been increasingly acknowledged, being involved in the 
male reproductive tract development and functions (Atanassova N et al, 2000; Berensztein EB et al, 2006; 
Course JF et al, 1999; Crescioli C et al, 2003; Delbes G et al, 2006; Raven G et al, 2006); but have not yet 
found an exact place in the above canonical scheme of sex determination. 
 12 
THE MALE GENITAL DEVELOPMENT 
 
During the first 8 gestational weeks (= 6 fetal weeks), genetically male and female embryos develop 
similarly and show sexually undetermined genital structures. By the end of the first month of gestation, the 
hindgut and future urogenital system, reach the surface of the embryo at the cloacal membrane on the 
ventral surface, where the cloacal folds develop, flanking the anogenital membrane. There, the most 
cephalad structure is the genital tubercle (GT), which will latter differentiate into a penis in males and a 
clitoris in females (Gilbert’s Developmental Biology, 7th Ed).  
 
The sexual dimorphic genital differentiation starts in humans around gestational weeks 9, after the fetal 
leydig cells start producing testosterone, particularly through its metabolite dihydrotestosterone (DHT) 
(Aaronson IA et al, 1997; Klonisch T et al, 2004; Wilson JD et al, 1993). In male fetuses this period is 
characterized by rapid elongation of the GT (Rey R and Picard JY, 1998; Allera A et al, 1995; McPhaul MJ, 
2002). In the female fetus, without the influence of testosterone, the genital tubercle develops into the 
clitoris, and the labioscrotal folds do not fuse, leaving labia minora and majora (Gilbert’s Developmental 
Biology, 7th Ed).  
 
 
 
Figure 3: Urogenital structure at week eight of human development. Adapted from: http://www.med.unc.edu/ 
embryo_images/unit-welcome/welcome_htms/contents.htm 
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As the male GT elongates, the urethral groove appears on its ventral aspect. It is defined laterally by 
urethral folds that are continuous with the urogenital (late cloacal) folds. The urethra forms by ventral 
growth and fusion of the urethral folds. This process begins proximally in the perineal region and extends 
distally toward the glans penis and results from epithelial seam remodeling, comprising internal cell 
migration and highly focalized apoptotic activity (Baskin LS et al, 2001a). 
 
Distally, the urethral groove terminates in a solid plate of epithelial cells (urethral plate) that extends into 
the glans penis. The solid urethral plate canalizes and thus extends the urethral groove distally into the 
glans by endodermal cellular differentiation (Kurzrock EA et al, 1999a; Kurzrock EA et al 1999b).  
 
THE MOLECULAR TEMPUS IN THE GENITAL DEVELOPMENT 
 
The formation of the external genitalia is a developmental process that involves genetic programming, cell 
differentiation, hormonal signaling, enzyme activity and tissue remodeling (Baskin LS, 2004; Cunha GR et al, 
2004). And it can be roughly divided in two stages:  
 
I. An initial hormone independent period, about 6 to 9 weeks of gestation, common to males and 
females, when the formation of the rudiments of the external genitalia and the initial outgrowth of 
the GT from the embryonic trunk take place, orchestrated by morphogenetic cell-cell interactions 
mediated via a spectrum of growth factors and other signaling molecules such as sonic hedgehog 
(SHH), fibroblast growth factors (FGF's), and bone morphogenetic proteins (BMPs), whose actions 
befall before the onset of the hormonal signaling. (Baskin LS, 2004; Haraguchi R et al, 2000; 
Kurzrock EA et al, 1999; Minelli A, 2002; Morgan EA et al, 2003; Ogino Y et al, 2001; Perriton CL et 
al, 2003; Petiot A et al, 2005; Suzuki K et al, 3003, Yucel S et al, 2004).  
 
II. The sexual dimorphic period, leading to the development of male or female genitalia, with 
differentiation of the GT into penis or clitoris, respectively. This period is hormone dependent and 
starts around gestational week 9 in humans. In male fetuses, the onset of masculinization of the 
male external genitalia coincides with Leydig cell-derived androgen production. This period also 
constitute a critical window of development, because a shift in the equilibrium between androgens 
and estrogens may induce disturbances in, and lead to maldevelopment of the genitalia (Akre O et 
al, 1999; Baskin LS et al, 2001b; Bay K et al, 2006; Hughes IA et al, 2006; Klonisch T et al, 2004; 
Panet-Raymond V et al, 2000; Stoll C et al, 1990; Yucel S et al, 2003). 
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ETIOLOGY OF HYPOSPADIAS 
 
Despite common, and with an increasing incidence (Paulozzi L et al, 1997; Toppari J et al, 2001), the 
etiology of hypospadias is still largely unknown. In up to 30% of the cases, particularly in severe 
hypospadias, a cause can be identified (Akre O et al, 1999; Baskin LS et al, 2001b; Utsch B et al, 2004). In 
the remaining 70% "idiopathic" hypospadias, a complex pattern of inheritance has been proposed (Fredell L 
et al, 2002; Frisén et al, 2004).  
 
ENVIRONMENTAL AND NON-GENETIC RISK FACTORS TO HYPOSPADIAS 
 
Environmental toxicants have been reported to increase the risk of giving birth to a boy with hypospadias, 
particularly the exposure to endocrine disrupters, which have been blamed for the increasing incidence of 
hypospadias (Paulozzi, 1997; Toppari et al, 2001). Furthermore, a maternal vegetarian diet, rich in 
fitoestrogens, the intake of diethylstilbestrol (DES), a potent estrogen, and loretadine have also been 
associated with hypospadias, with conflicting results in some studies (Bay L et al, 2006; Klip H et at, 2002; 
North K et al,2000; Storgaard L et al, 2006).  
 
One of the best-established risk factors for hypospadias is low birth weight (Akre et al. 1999; Chen YC and 
Woolley PV, 1971; Gatti JM, 2001; Monteleone Neto R et al, 1981; Weidner IS et al, 1999). Fredell et al have 
suggested that this association is independent from genetic factors in monozygotic twins discordant for 
hypospadias, where the twin with the lower birth weight is affected with hypospadias. In addition, the birth 
of boys with hypospadias is more often associated with a higher rate of weak contractions, lower placental 
weight, induced deliveries and caesarean. And the incidence of hypospadias in monozygotic twins is 8.5-
fold that in singletons. Those evidences point to deficits of the fetal-placental-maternal interaction (Avellan 
L et al, 1977; Calzonari E et al, 1986; Hussain N et al 2002).  
 
Hypospadias is also more common in infants born after in-vitro fertilization (IVF), particularly with intra-
cytoplasmatic sperm injection (ICSI), (Ericson A and Källén B, 2001, Källén B et al 2005). The association 
with IVF and hypospadias has been related to paternal subfertility (i.e. by genetic factors) (Wennerholm UB 
et al 2000), and also to the gonadotropic hormones used during the IVF procedure may interfere with 
androgen production, as well as progestins administered after embryo transfer (Meijer WM et al 2006, 
Sorensen HT et al 2005).  
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GENETIC AND MOLECULAR ASPECTS OF HYPOSPADIAS 
 
Several observations support a strong genetic influence in hypospadias: Familial clustering is seen in up to 
25% of cases. A concordance rate of 27% (6 of 22) in monozygotic twins and of 9% (1 of 11) in dizygotic 
twins was reported in hypospadias (Fredell L et al, 1998), which is in accordance with previous results 
(Bauer et al, 1979; Calzolari E, et al, 1986; Chen YC et al, 1971; Czeizel A et al, 1979; Monteleone Neto R et 
al, 1981; Stoll C et al, 1990). Furthermore, a search at the OMIM database finds more than 150 entries for 
hypospadias. From these, several genetic factors have been identified to be associated both with isolated 
or syndrome-associated forms of hypospadias.  
 
GENETIC DEFECTS IN HORMONAL PATHWAYS 
 
Since the masculinization of the urogenital structures is an androgen-dependent process (Aaronson IA et al, 
1997; Kim KS et al, 2002; Yucel S et al, 2003), it is not surprising that impairment of the androgen 
biosynthesis and activity can induce hypospadias (McPhaul MJ, 2002). Abnormalities in the androgen 
receptor (AR) and in 5-alpha-reductase type 2 (SRD5A2), the enzyme that mediates the conversion of 
testosterone into the more potent androgenic derivative DHT, have been found in hypospadias (Allera A et 
al, 1995; Silver RI et al, 1999; Wilson J et al, 1993).  
 
Moreover, some authors report endocrine abnormalities in boys with hypospadias, particularly the more 
severe cases (Aaronson IA et al, 1997; Allen TD, Griffin JE, 1984; Nonomura K et al, 1984; Gearhart JP et al, 
1990; Hyun G et al, 2004; Shima H et al, 1986; Silver RI, 2004): Some reports suggest an abnormal 
androgenic milieu in boys with hypospadias, who present either hypergonadotropic hypogonadism or 
hypogonadotropic hypogonadism, i.e. that these boys have either an impaired testicular testosterone 
production or an impaired pituitary gonadotropin production, respectively. 
 
Defects at various steps of the steroid biosynthesis pathway can also induce hypospadias in patients with 
an XY karyotype (Aaronson IA et al, 1997; Moisan AM et al, 1999; Denes FT et al, 2000). In addition, defects 
in the anti-Müllerian hormone (Imbeaud Set al, 1995), or in the LH and its receptor (Martens JW et al 1998; 
Mendonça BB et al, 2000), account for a very small number of hypospadias.  
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OTHER GENETIC DEFECTS  
 
Some rare genetic syndromes are associated with hypospadias. Examples are the ATR-X syndrome, 
campomelic dysplasia, and the hand-foot-genital syndrome with mutations in the corresponding 
transcription factors XH2 (Gibbons RJ et al, 1995), SOX9 (Cameron FJ et al, 1997; Wagner T et al, 1994), and 
HOXA13 (Mortlock DP et al, 1997; Utsch B et al, 2002), respectively. Chromosome rearrangements in 46,XY 
individuals with hypospadias have also been reported: 13q and 14q (Kilic N et al, 2005); 6p and 17q 
(Mansouri MR et al, 2006); 1q and 18q (Frizell ER et al, 1998); 8q and 20p (Tar A et al, 1997); 3p and 4q 
(Hegmann KM et al 1996); 7q and 18q (Johnson DD et al, 1986). Abnormalities in the sex chromosomes 
have also been found, such as 46,XX/46,XY chimerism (Benirschke K et al 1972) and mosaicism, such as 
45,X/46,XY; 46,XX/47,XXY; 45,X/46,XY/47,XYY (Federman DD et al, 1995; Yordam N et al, 2001). 
 
COMPLEX GENETIC ETIOLOGY 
 
The aforementioned defects, as well as other rare genetic disorders, do not explain the vast majority of the 
non-syndromic hypospadias cases (Avellan L, 1977; Frydman M et al, 1985; Lowry RB et al, 1976; 
Martens JW et al 1998; Mendonça BB et al, 2000). For most of the cases, pedigree analyses indicate a 
heterogeneous, complex pattern of inheritance for hypospadias, with several genetic and environmental 
factors interacting, a model that yields high heritability indices, ranging from 57% to 74% (Harris EL, 1990; 
Stoll C et al, 1990). A complex segregation analysis of 2005 pedigrees with at least one member with 
hypospadias, showed a heritability of 0.99 and evidence for multifactorial inheritance; furthermore, the 
authors suggested that hypospadias might be due to monogenic effects in a small proportion of the 
families, but that there is a multifactorial cause for the majority of the cases (Fredell L et al, 2002).  
 
Studies on candidate genes, such as the AR and the SRD5A2, have evidenced that polymorphisms in these 
genes may individually increase the risk to hypospadias; but are not sufficient to produce hypospadias. 
Variants in the AR, such as CAG and GGN repeat polymorphisms; and in the SRD5A2, such as the A49T, and 
the V89L gene variants are associated with this inborn error of development (Klonisch T et al, 2004; Sharpe 
RM, 2006; Silver R et al, 1999).  
 
Frisén et al, in 2004, reported a genome-wide linkage analysis for hypospadias susceptibility genes; and 
suggestive linkage was found in 4 chromosome regions: 9q22 (in Swedish and Middle Eastern families), 
2p11, 10p15 and 10q21 (only in Swedish families), providing a basis for outlining the complex genetic 
background of hypospadias.  
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HYPOSPADIAS: ANALYSIS OF A COMPLEX GENETIC DISORDER 
 
Hypospadias is a common complex genetic disorder for most of the cases, as evidenced by Fredell et al in 
2002, involving the combination of several genetic and environmental risk factors. Genetically complex 
traits and disorders are those which are not inherited in an easily determined manner: Although they often 
cluster in families, no clear-cut pattern of inheritance is identified. This makes it difficult to determine a 
person’s risk of inheriting or passing on these disorders. It is the case of common disorders, such as heart 
disease, hypertension, diabetes, obesity, several forms of cancer, cleft palate, low IQ or autism, which 
consist in a serious burden to the society and to the medical resources.  
 
Mapping the genes that contribute to complex diseases has become a major challenge of the post-genome 
era, since the determination of the genetic variants underlying these disorders may provide new insight 
into disease etiology, suggesting novel pharmaceutical targets; and could lead to genetic screening to 
identify individuals at increased risk. 
 
GENETIC ARCHITECTURE UNDERLYING COMMON DISEASES 
 
In contrast with monogenic disorders, which are controlled by genes of large effect and show simple 
patterns of inheritance within families, the genetic architecture underlying complex diseases is poorly 
understood: A defining feature of complex phenotypes is that no single locus contains alleles that are 
necessary or sufficient for disease. For a given disease, an individual's risk probably depends on some 
unknown function of genetic, environmental/lifestyle and stochastic factors. Some disorders may be 
explained by the cumulative result of few variants in a few genes; in other cases, the combination of a large 
number of common genetic variants, each contributing with small effects, influence the risk to a disease. 
Some disorders may also be determined by the result of an interaction between one or more genetic 
variants and environmental or non-genetic disease risk factors, including probably also imprinting and 
epigenetics. Furthermore, we do not yet know whether susceptibility alleles in complex disorders are 
common or rare, neutral or deleterious, few or many (Weiss et al, 2000; Wright AF et al, 2001). 
 
One hypothesis about complex genetics architecture proposes that common, invisible-to-selection, weakly 
associated alleles influence the risk to complex disorders. The genetic risk effects would be due to disease 
loci where there is one, or a very small number of common variants; this is the common disease–common 
variant hypothesis (Lander ES, 1996). Under this hypothesis, one can assume that of there is little allelic 
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heterogeneity within loci. And therefore it may be possible to map susceptibility mutations through linkage 
disequilibrium with genotyped markers. Supporting this hypothesis is the fact that susceptibility variants 
involved in complex diseases have low or medium penetrance, and are probably little affected by selection 
(Pritchard JK et al, 2002).  
 
In opposition, some authors suggest that few variants of clinical consequence will actually be common 
(Figure 4). Indeed, modeling of complex diseases taking into account the genetic variation at disease-
susceptibility loci, the evolutionary processes, including mutation, genetic drift, and the possibility of 
selection, has predicted that neutral susceptibility alleles do not contribute much to the genetic variance 
underlying disease. These neutral alleles tend to be either lost or close to fixation in the population 
(Pritchard et al, 2001). 
 
It seems more likely that most of the genetic variance underlying complex diseases is due to loci where 
susceptibility gene variants are mildly deleterious. At such loci, the total frequency of susceptibility 
mutations may be quite high, meaning a high allelic heterogeneity. Such heterogeneity may be greater in 
more physiologically complex disorders (Pritchard JK, 2001; Wright AF et al, 2001). Under these 
assumptions, direct sequence analysis may be needed to identify genetic variants in complex disorders. 
 
 
 
 
Figure 4: Genetic dissection of complex traits. Common disease-common variant hypothesis proposes that complex 
traits are the result of the combination of multiple risk gene variants; the multilocus-multiallele hypothesis, suggests 
that a few tens of heterogeneous disease loci, but not many hundreds, interact in different combinations in different 
individuals to influence the trait (adapted from Wright AF et al, 2001). 
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Between these two hypotheses, the answers and paths that define the best approach to map complex 
diseases will be trait specific. And probably no single approach will be sufficient. An analysis of the trait, by 
defining the phenotype, and determining an eventual genetic component, through family studies, 
heritability studies, segregation analysis, twin studies, adoption studies, heritability studies and/or 
population based risks to relatives and probands, must be consistently done. After a careful experimental 
design, strategies for genetic mapping are evaluated. The aims of genetic analyses of complex disorders are 
to identify the genetic risk factors and to model their role, the interactions between them and with 
environmental factors by statistical and bioinformatic resources. The parameters to consider for designing 
a genetic study of a complex disease are at different levels: 
 
I. The knowledge of pathophysiological process: 
- If specific hypotheses on the role of particular genes are available, the candidate gene 
approach can be applied. It consists in choosing markers near the candidate gene. 
- If unknown, a genome scan approach may be set up using markers distributed over the 
genome. 
 
II. The methodological strategy most suitable according to the kind of genetic information available: 
- Linkage studies which consist in finding a physical linkage between a marker and a gene. 
These studies deal with family design. 
- Association studies which consist in finding a correlation between several factors and the 
disease. These studies imply in general unrelated individuals or a population. 
- Methods testing at the same time association and linkage: The most popular such method 
uses the parental genotyping information and is known as the Transmission Disequilibrium 
Test (TDT); TDT uses healthy relatives as controls, overcoming the problem of population 
stratification of case-control studies, and tests for association in presence of linkage. 
 
STRATEGIES FOR MAPPING IN COMPLEX GENETICS 
 
LINKAGE ANALYSIS 
 
Linkage mapping, also called positional cloning, is the process of systematically scanning the DNA genomes 
of various members of families using regularly spaced, highly variable (polymorphic) DNA segments whose 
position is known (genetic markers). This approach is an unbiased search of the entire genome without any 
preconceptions about the role of a certain genomic region or gene. Genetic linkage relies on the tendency 
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for haplotypes to be passed on to the next generation intact, without recombination events. If a marker can 
be identified that passed down through a family such that it is consistently accompanies the disease of 
interest, this suggests a gene with functional effect that is located close to that marker. Linkage analysis 
methods can be applied to both major gene disorders - parametric linkage- and complex diseases - model-
free and non-parametric linkage. Successful mapping of complex disorders depend on the ability to 
adequately model the phenotype, and the genetics underlying it (Forabosco P et al, 2005; Mayeux R, 2005; 
Risch N, Merikangas K, 1996).  
 
Several potential DNA regions that may contain susceptibility genes for hypospadias have been identified in 
our lab (Frisén L et al, 2004); and fine mapping of these regions is still ongoing. Linkage analysis was not the 
focus of this thesis. 
 
ASSOCIATION ANALYSIS 
 
The goal of association studies is to identify patterns of polymorphisms that vary systematically between 
individuals with different disease states and could therefore represent the effects of risk-enhancing or 
protective alleles. Association differs from linkage in it relies on shared common ancestry in populations; 
and therefore is able to detect smaller genetic effects on disease susceptibility. A statistically significant 
difference in association studies indicates that: 1) the studied polymorphism has a causal role; 2) the 
polymorphism has no causal role but is in LD with a causal variant; 3) the association is due to some 
underlying stratification or admixture of the population. To avoid the last, it is necessary to be careful 
about the matching of cases and controls, for a maximum of potential confounders, such as age and sex, 
and most importantly, ethnicity, in addition to the status of case or control (Balding DJ, 2006; Forabosco P 
et al, 2005). 
 
Direct association studies analyze target, polymorphisms. This type of study is the easiest to analyze and 
the most powerful; and is based on an educated guess about the genetic basis of a disorder, on a gene 
and/or on a putative functional gene variant (Collins et al. 1997; Risch e 1996). Direct association studies 
may be a good choice for detecting gene variants underlying complex disorders where the risk associated 
with any given candidate gene is relatively small. The difficulty in direct association studies is the 
identification of candidate gene variants: Undoubtedly, we do not know enough about the genome nor 
about complex genetics to predict which variants may have such effects. Thus, direct association studies 
only have the potential to discover a few of the genetic causes of disease and disease-related traits. 
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Indirect association studies, in the other hand, rely on linkage disequilibrium (LD) to detect disease-causing 
variants in the proximity of the tested polymorphisms. This is the most commonly used form of association 
studies in complex diseases, particularly in the study of candidate gene/ genomic region.  
 
LD refers to the non-independence of alleles at different sites. A given pair of intra-chromosomal markers 
are said to be in LD if they segregate together more often, and recombine less, than would be expected 
under independent assortment. Hence, the measure of LD between two markers will indicate the extent to 
which the genotype of one marker will predict the state of the other (Balding DJ, 2006; Forabosco P et al, 
2005).  
 
Recent advances in high throughput genotyping technology mean that screening of the all genome for 
disease associations is becoming feasible. However, even as whole genome studies are increasingly used, 
candidate gene studies will continue to play an important role in the study of complex genetic disorders.  
 
ASPECTS OF THE ANALYSIS IN ASSOCIATION STUDIES  
 
Having selected candidate genes or candidate genomic regions, an association study must be appropriately 
designed and analyzed to optimize the possibility of identifying causal variants, as well as of delivering 
reliable negative results, which are important to reduce duplication of effort and conflicting reports.  
 
SNP TAGGING 
 
By understanding the LD structure of the genome, frequency differences between affected and unaffected 
individuals do not need to be measured in all SNPs; but only in a subset of tag SNPs, which serve as proxy 
for the remaining SNPs and represent the total sequence variation in a target gene or genetic region. 
Tagging refers to the methods to select these SNPs (Carlson CS et al 2004; Zeggini E et al, 2005); and can be 
done in appropriate softwares, such as the Haploview (Barret et al, 2005).  
 
Previously, this was a laborious initial step in study design, implying the typing and analysis of an extensive 
SNP set in a few individuals. Now with the International HapMap Project, it is possible select tag SNPs on 
the basis of publicly available data. The population that underlies a particular study will typically differ from 
the populations for which public data is available. However, recent studies indicate that tag SNPs often 
transfer well across populations (Gonzalez-Neira A et al, 2006). 
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PRELIMINARY ANALYSES IN ASSOCIATION STUDIES 
 
The quality of the data should be checked thoroughly before starting the analysis. Testing for Hardy–
Weinberg equilibrium (HWE) is one way to do it (Nielsen, DM et al 1998): deviations from HWE can be due 
to typing errors, such a mutant PCR-primer site, or because of a tendency to miscall heterozygotes as 
homozygotes, inbreeding, population stratification or selection. Deviations from HWE can also be a 
symptom of disease association, the implications of which are often under-exploited; and can also arise in 
the presence of deletion polymorphisms or segmental duplications that could be important in disease 
causation (Conrad DF et al, 2006; Bailey JA et al, 2006).  
 
Testing for deviations from HWE can be carried out using a Pearson goodness-of-fit test with a χ2 null 
distribution (Wigginton JE et al 2000). The Haploview (Barret et al, 2005) software performs this test, 
calculating a HWE p-value, which is the probability that its deviation from HWE could be explained by 
chance. 
 
MEASURES OF LD AND ESTIMATES OF RECOMBINATION RATES 
 
It is usually of interest to summarize LD over the tested genomic region, since if a causal polymorphism is 
not genotyped, we can still hope to detect its effects through LD with polymorphisms that are typed. One 
approach is to compute local averages of pairwise values of D' and r2, two proposed measures of LD (Devlin 
B et al, 1995). D', the normalized disequilibrium coefficient, which ranges from 0 to 1, is sensitive to even a 
few recombinations between the loci. The squared correlation coefficient, r2, reflects statistical power to 
detect LD and can be an indicator of the sample size that would have been required to detect the disease 
association.  
 
The LD values over a region can be illustrated diagrammatically with colors encoding different values 
(Abecasis GR et al, 2000), such as presented by the Haploview software (Barrett JC, 2005). LD maps provide 
another solution, fitting an exponential decay function to D' values, and the decay parameter provides a 
measure of local LD (Tapper W et al, 2005).  
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TESTS OF ASSOCIATION IN SINGLE SNPS 
 
The analysis of SNP genotypes in a case–control study is performed by comparing frequencies between 
affected and unaffected individuals. Usual methods in epidemiology for case-control design can be used: 
2X3 contingency tables with a Pearson test (2-df), considering the null hypothesis of no association. For 
complex traits, it is widely assumed that contributions to disease risk from individual SNPs will often be 
roughly additive. The power to detect risks may improve by counting alleles rather than genotypes using a 
2X2 table, and a Pearson test (1-df), provided that the frequencies are in HWE (Sasieni PD, 1997). The 
general statistic tests have reasonable power regardless of the underlying risks. Bayesian methods may be a 
good option when a priori predictions about the nature of disease risks can be explicated (Lunn, D et al 
2006). 
 
Regression analysis is another way of analyzing the data. In its simplest form, regression analysis involves 
finding the best straight line relationship to explain how the variation in an outcome (or dependent) 
variable, Y, depends on the variation in a predictor (or independent or explanatory) variable, X. Once the 
relationship has been estimated we will be able to use the equation: Yij= a+bXij+εij, where a is the 
intercept, b is the slope and ε is the error term. The model picks up the unpredictable part of the response 
variable Yi. The x's and Y's are the data quantities from the sample or population in question (where Yij 
is the trait value for individual i with genotype j and Xij is the mean effect of genotype j); and a and b are 
the unknown parameters to be estimated from the data (Balding DJ, 2006). The test requires the trait to be 
approximately normally distributed for each genotype, with a common variance.  
 
Alternatively, logistic regression may be used to, as it makes no assumption about the distribution of the 
independent variables; they do not have to be normally distributed, linearly related or of equal variance 
within each group. Furthermore, it offers a flexible tool that can readily accommodate other variables, such 
as environmental interactions or covariates such as sex or age of onset. Logistic regression applies 
maximum likelihood estimation after transforming the dependent variable into a logit: logit (Y) = log [Y/ (1 
-Y)]. The value of logit is equated to either β0, β1 or β2, according to the genotype of individual (β1 for 
heterozygotes). The likelihood-ratio test of this general model, against the null hypothesis β0 = β1 = β2, has 
2 df. Tests for recessive or dominant effects can be obtained by requiring that β0 = β1 or β1 = β2 (Balding DJ, 
2006).  
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TESTS OF ASSOCIATION IN MULTIPLE SNPS 
 
Analyzing SNPs one at a time can neglect information in their joint distribution (Waldron ERB et al, 2006). 
Logistic regression analyses for a set of n SNPs in a candidate gene is a natural extension of the single SNP 
analyses discussed above: there is now a coefficient (β0, β1 or β2) for each SNP, leading to a general test 
with 2n df. Interactions between SNPs can be investigated, being potentially useful for investigating 
epistatic effects.  
 
Haplotype-based methods can also be used to capture the correlation structure of SNPs, particularly in 
regions of little recombination. There are statistical methods, and softwares that implements them such as 
Haploview (Barret et al, 2005) and Unphased (Dudbridge F, 2003), for inferring haplotype frequencies from 
the genotypes of related and unrelated individuals (Marchini J et al, 2006). The simplest analysis involves 
testing in a 2Xn contingency table, where n denotes the number of distinct haplotypes. Alternative 
approaches, based on the estimated haplotype proportions among cases and controls, without an explicit 
haplotype assignment for individuals, compare the product of separate multinomial likelihoods in the two 
groups with that obtained by combining cases and controls (Tzeng JY et al, 2003).  
 
The haplotype analysis of unrelated individuals has some caveats. One of them is that usually these 
approaches rely on assumptions of HWE and of near-additive disease risk. Furthermore, haplotypes cannot 
be known for sure in population based studies. Instead, phase must be inferred with a certain degree of 
uncertainty. Therefore, when assessing the overall significance of any finding, this must be taken into 
account, particularly when LD between markers is low. Moreover, the inclusion of many rare haplotypes in 
analyses can decrease the power to detect association due to too many degrees of freedom. And to 
combine all rare haplotypes into a dustbin category might miss their separate effects. Some methods are 
emerging to try to overcome this and other aspects (Ke XY et al, 2004; Lin DY, Zeng D, 2006; Schaid DJ et al, 
2002). Despite their clear usefulness in genetic association studies, the limitations of haplotype-based 
methods should be considered when performing the analysis (Browning SR, 2006).  
 
MISSING GENOTYPE DATA 
 
Missing genotypes can be predicted, maximizing the use of the observed data, with appropriate softwares 
based on the observed genotypes at neighboring SNPs (Little RJA, Rubin DB, 2002). These methods either 
seek a best prediction of a missing genotype, such as a maximum-likelihood estimate (single imputation), as 
Unphased (Dudbridge F, 2003); or randomly select it from a probability distribution (multiple imputations). 
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These analyses needs, though, to be made critically (Balding DJ, 2006; Little RJA et al 2002; Souverein OW 
et al, 2006).  
 
MULTIPLE TESTING 
 
The analysis of association data usually generates a lot of tests, and consequently the problem of multiple 
testing emerges. The error rate of each test made is defined by [1 − (1 − α)]n, n being the number of 
independent tests performed. One conservative solution to multiple testing can be provided by the 
Bonferroni correction, which consists in multiplying the p-value by the number of performed tests (Balding 
DJ, 2006).  
 
Other way to take into account the multiple statistical tests is to correct the p-values by performing 
permutations. Permutation testing is a nonparametric re-sampling approach to statistically test hypotheses 
about populations, based on samples of data. It is performed as follows: The trait values are randomly 
shuffled between subjects a number of times. In each permutation the minimum p-value is compared to 
the minimum p-value observed in all the analyses in the original dataset. Both Haploview and Unphased 
softwares provide a framework for permuting association results in order to obtain a measure of 
significance corrected for multiple testing biases.  
 
ADDITIONAL REMARKS 
 
Since no test is absolute, and all tests have limitations, the application of different algorithms to the same 
data set can be useful to increase the degree of evidence. The importance of replication studies is 
undeniable. And additional evidences, at the physiological and functional level are desirable. 
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CANDIDATE GENES IN HYPOSPADIAS 
 
In this thesis, a candidate gene strategy was chosen to investigate genes, which take part in the urethral 
development, and with a potential role in the etiology of hypospadias. Several aspects of the development 
of the GT and the male genitalia, revealed through the study of model organisms (reviewed by Stadler HS, 
2003), and humans (such as Crescioli C et al, 2003; Kim KS et al, 2002; Pelletier G et al, 2000; Shapiro E et al, 
2006; Westberg L et al, 2001; Liu Bet al, 2005; Hughes IA, 2000), were the rationale behind the selection of 
genes: the early developmental genes FGF8, FGF10, FGFR2 and BMP7; FKBP4 that codes to a co-chaperone 
of the AR; the ESRs; and ATF3, an hormone responsive gene. 
 
EARLY DEVELOPMENTAL GENES 
 
The outgrowth and patterning of the GT start by gestational week 6 in humans, before the sexually 
dimorphic phase, i.e., in the absence of endocrine signals. This period, as shown in studies of model 
organisms, is marked by a network of morphogenetic events, coordinated by a series of signaling 
molecules, particularly fibroblast growth factors (FGF’s), sonic hedgehog (SHH), HOX13 gene products, and 
bone morphogenic proteins (BMPs) (Baskin LS, 2004). This process is orchestrated by the urethral plate 
epithelium (UPE), at the GT, which has polarizing activity (Haraguchi et al, 2000; Kurzrock EA et al 1999a; 
Murakami and Mizuno, 1986). Moreover, the balance between cell proliferation and apoptosis seems to be 
important for the genital development, influenced by the interaction of positive growth regulators (FGF 
family or SHH) and negative growth regulators (such as BMP 2, 4 and 7) (Suzuki K et al, 2003).  
 
The distal UPE region in mice is initially marked by the expression of fgf8 (also called androgen-induced 
growth factor, AIGF), which regulates the initial outgrowth of the GT outgrowth and the expression of 
mesenchymal gene expression, such as fgf10 (Haraguchi et al, 2000). The expression of Shh is also observed 
in the UPE; and regulates the expression of fgf8, as well as several mesenchymaly expressed molecules, 
fgf10, and hoxd13 (Perriton CL, et al, 2002). The shh null mice (Yucel S et al, 2004) display complete GT 
agenesis, with increased cell death and reduced cell proliferation, indicating that Shh is essential for the 
initiation of the GT outgrowth, polarized gene expression and cell surviving. The Gli family of transcription 
factors, as target of Shh; is also required for the normal development of the GT (Haraguchi et al, 2001; 
Motoyama et al, 1998). Bmp genes (such as bmp 2, 4 and 7), their antagonists (nog and chordin) and 
receptors (bmpr1 and bmpr2) are also expressed in the UPE, and in the distal-ventral mesenchyme 
adjacent to it, acting as negative growth regulators (Suzuki K et al, 2003).  
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HOX13 gene products also take part in the urethral development. Both hoxa13 and hoxd13 are strongly 
expressed in the mesenchyme of the GT (Warot et al., 1997). Some hox13 gene mutations affect the 
development of the distal (cloacal) portion of the hindgut and the GT (Kondo et al, 1996; de Santa Barbara 
P et al, 2002; Warot X et al, 1997). In a knock-out mouse model, the loss of hoxa13 function (hoxa13-/-) 
affects the differentiation and maturation of the urethral epithelium, (Morgan EA et al, 2003), with a 
marked reduction of fgf8 and bmp7 expression, which leads to coronal hypospadias. In these mice, both 
programmed cell death and cell proliferation are reduced in genital-shelf mesenchyme.  
 
Fgf10 is another important morphogen of the most distal mesenchymal GT structures (Haraguchi Ret al 
2000). Mutant mice lacking fgf10 or its receptor, the fibroblast growth factor receptor 2 isoform IIIb (fgfr2-
IIIb), exhibit normal corporal bodies, but disturbed urethral plate ventral fusion, consistent with 
hypospadias. In these mice, urethral signaling regions are established, but cell proliferation is prematurely 
arrested and maturation of the urethral epithelium is disrupted. Interestingly, these genes are downstream 
targets of AR during external genital development, since the loss of fgfr2-IIIb and fgf10 expression in the 
urethra, and associated hypospadias phenotype, is observed as an effect of androgen antagonists (Yucel S, 
et al, 2004; Petiot A et al).  
 
Based on the fgf10, fgfr2-IIIb and hoxa13 knock-out mice phenotypes, mutations of the FGF10, FGFR2, 
FGF8 and BMP7 genes could underlie hypospadias in humans. We explored this hypothesis in a set of 
familial cases of non-syndromic hypospadias.  
 
FKBP52, A CO-CHAPERONE OF THE ANDROGEN RECEPTOR 
 
ANDROGENS IN THE MALE URETHRAL DEVELOPMENT 
 
Androgens start being produced by fetal Leydig cells around gestational week 9 in man, marking the 
beginning of the sexually dimorphic phase of development. Androgens are crucial for the survival and 
differentiation of the Wolffian duct. The masculinization of the external male genitalia is dependent on 
testosterone, and specially its conversion via SRD5A2, to the more potent DHT (Rey R et al, 1998). 
Moreover, androgens have a direct effect on the fusion of the urethral fold, as demonstrated by an 
acceleration of urethral fold fusion and a longer urethral tube in mice treated with androgens in uterus 
(Yucel S, 2003). Androgens acts upon the male sexual development through its receptor (AR), which is a 
hormone induced transcription factor.  
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The expression of AR and SRD5A2 has been documented in the human developing male urethra (Kim KS et 
al, on 2001). Between 12 and 14 weeks of gestation, AR is localized on the epithelial cells of the urethral 
plate in the glans, the tubular urethra of the penile shaft, and stromal tissue surrounding the urethral 
epithelium. Between 16 and 20 weeks gestation, AR expression is observed in urethral epithelial cells, 
greater along the ventral aspect of the glandular urethra. The expression of SRD5A2 localizes to the stroma 
surrounding the urethra, especially along the urethral seam area in the ventral portion of the remodeling 
urethra (Kim KS et al, 2001). These evidences indicate an important role of androgens in the urethra seam 
formation.  
 
Abnormalities in the AR and on the androgen biosynthetic pathway have been found in hypospadias 
(Aaronson IA et al, 1997; Denes FT et al, 2000; Klonisch T et al, 2004; Moisan AM et al, 1999; Sharpe RM, 
2006; Silver R et al, 1999). And it is possible that other aspects of the androgen action may also be related 
with this inborn error of development. One of such aspects is the complex AR regulation. As a steroid 
receptor, AR’s activity is subjected to regulation by co-regulators and general transcription factors, which 
modulate the transcription of AR target genes. And AR’s regulatory molecules can be regarded as possible 
candidates for androgen related dependent disorders (Hughes IA, 2000).  
 
In fact, hormone-resistance syndromes have already been attributed to disorders of co-regulator proteins. 
In 1999 MI New et al described two sisters with multiple partial hormone resistance, in which a co-activator 
defect was proposed as underlying mechanism (New MI et al, 1999). This report was followed by a case of 
clinical androgen insensitivity described by Adachi et al, 2000, with normal AR sequence, but in which an 
unknown protein that interacts with the AF-1 region was missing (Adachi M et al, 2000). Furthermore, it 
has been proposed that the dysfunction of one member of the large family of co-regulators is likely to 
produce mild hormone resistance, since compensatory mechanisms might be activated if one member of 
these complexes is dysfunctional, a scenario compatible with isolated hypospadias (Hughes IA, 2000). The 
phenotype of the mice lacking fkbp52 (52KO) supports this concept.  
 
FKBP52, AND THE REPRODUCTIVE PHENOTYPE OF THE 52KO MOUSE 
 
The co-regulator FKBP52, is a 90-kDa heat shock protein (Hsp90)- binding immunophilin found in steroid 
receptor complexes, which directly controls their transcriptional activity (Pratt WB et al, 1997; Tranguch S 
et al, 2005; Wochnik GM et al, 2005). Mice lacking all coding exons of fkbp4 (52KO), the mouse gene 
encoding fkbp52, were generated in order to assess the physiological importance of this molecular co-
chaperone. Surprisingly, 52KO males developed penile hypospadias with 100% penetrance (Cheung-Flynn J 
et al, 2005; Yong W et al, 2006). Some 52KO mice also showed dysgenesis of anterior prostate and seminal 
vesicle, infertility and unilateral undescended testis. No abnormalities in testicular histology were observed 
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in 52KO males; and gross defects in other organs and systems were ruled out. Besides, and contrary to 
what was expected, no alterations related to other steroid receptors were identified.  
 
Since Fkbp52 is critical to AR transcriptional activity (Cheung-Flynn J et al, 2005), the authors conclude that 
FKBP52 plays an important physiological role in up-regulating AR activity in some murine male reproductive 
tissues, mediating the association of the AR with Hsp90, establishing and maintaining hormone binding 
ability. Therefore, hypospadias can be attributed to the loss of Fkbp52-enhanced AR function during 
urethral development. Based on the 52KO mouse phenotype, variants of the FKBP4 sequence and 
expression could induce hypospadias in humans, underlying defects of the androgen action that are not due 
to AR gene mutation.  
 
ESTROGEN RECEPTORS, AND THEIR ROLE IN THE MALE REPRODUCTIVE TRACT 
 
Estrogens are steroid hormones, which, through the regulation of the transcriptional activity of the 
estrogen receptors (ESRs), elicit a myriad of biological responses, with known important roles in 
development, reproduction, homeostasis, (Ascenzi P et al, 2006; Leung YK et al, 2006) and disease 
progression (Deroo and Korach, 2006). ESRs, as the AR, belong to the family of nuclear transcription factors. 
There are two ESR molecules: ESR1 and ESR2, products of separate genes (ESR1 and ESR2) in distinct 
chromosomes (locus 6q25.1 and locus 14q23-24.1, respectively). These two forms have different affinities 
and responsiveness, different modulators, different tissue distribution and different gene regulatory sites. 
However, both share a general domain structure common to ligand-modulated nuclear transcription 
factors (Figure 5).  
 
ESTROGENS AND THE MALE REPRODUCTIVE TRACT  
 
Traditionally, the male reproductive system was considered to be controlled by both gonadotropins and 
androgens. Estrogens were, for many years, considered to be the female hormones. It was not before the 
70ies that testis were acknowledged as a source of estrogens (Kelch et al, 1972). This was followed by 
evidence of testosterone aromatization into estradiol in the male reproductive tract; as well as of estrogens 
synthesis in peripheral tissues of normal men (MacDonald et al, 1979; Valladares et al, 1979). More 
recently, it has been showed that both immature and mature germ cells and spermatozoa are able to 
produce estrogens (Aquila S, 2002; Carreau S et al, 2001; Carreau S et al, 2002). Further molecular 
characterization of the ESRs (Evans RM, 1988), together with gene-expression studies on ESR1 (Couse JF et 
al, 1997) and on ESR2 (Couse JF et al, 1997; Enmark E et al, 1997) have progressively clarified the 
 30 
relationships between estrogens and male reproductive function, particularly in fertility (Herbst AL et al, 
1975; Sharpe RM, 1998; Wilcox AJ et al, 1995). 
 
Active ESRs are found during male reproductive structures (Berensztein EB et al, 2006; Carreau S et al, 
2002). In mice, esr1 is abundant in early Leydig cells, as well as in the developing, and mature, efferent 
ductules. In the seminiferous epithelium and in the epididymis of the male fetus, esr2 expression is higher 
that esr1, the latter being absent or very low; esr2 is the isoform which prevails in Leydig cells and testis 
during fetal life, suggesting a major role of esr2 in the development and function of male reproductive 
structures until birth (Baskin LS et al, 2001b; Couse JF et al, 1999; Dietrich W et al 2003; Jefferson WN et al, 
2000).  
 
Functional ESRs are expressed in the human reproductive tract. In the testes, ESR2 immunoreactivity was 
detected in nuclei of Sertoli and Leydig cells; ESR1 is only expressed in Leydig cells. In the efferent ducts, 
only ESR2 could be detected. In the prostate, ESR2 is localized in the nucleous of basal and secretory cells in 
alveoli as well as in stromal cells; no ESR1 is detected (Pelletier G, El-Alfy M, 2000). Similar studies were 
performed in the penis (Dietrich W et al 2003): ESR2 is strongly expressed in the corpus cavernosum, 
corpus spongiosum, penile and urethral epithelia; while ESR1 is only found sporadically in the penile and 
urethral epithelia.  
 
Figure 5 Comparison of domain structures of human ESR1 and ESR2. The estrogen receptors are members of the 
nuclear receptor superfamily and share a domain structure, which is depicted schematically. The ESRs have six 
domains, A–F, and the number of amino acids in these domains, as well as the functions associated with these 
domains, are indicated for each form of ESR. AF-1 and AF-2 refer to regions that mediate the transcriptional activation 
functions of the ERs (adapted from Ascenzi P et al, 2006; Kuiper GG et al, 1997; and Nilsson S et al, 2002).  
 
ESR2 
ESR1 
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ESRS IN THE MALE URETHRAL DEVELOPMENT 
 
The importance of estrogens in male genito-urinary development has been increasingly acknowledged and 
corroborated by the presence of active ESRs in the developing male urethra. In humans, the ESR2 is 
expressed ubiquitously in the male external genitalia as early as 9 weeks of gestation; and expression 
remains intense at 22 weeks, being the predominant subtype. ESR1 expression is found only after 16 weeks 
of gestation, localized to the squamous epithelium of the distal dorsal urethra and the ventral junction of 
the glans epithelium and inner prepuce (Shapiro, E, et al, 2006). Moreover functional estrogen receptors 
localize at the same structures as the androgen receptors in the developing murine male external genitalia, 
indicating interactions between effects exerted by the two steroid hormones (Crescioli C, 2003).  
 
Studies in both animal models and humans suggest that the inappropriate exposure to estrogens in utero 
and during the neonatal period impairs the urethral development (Herbst AL et al, 1975; Sharpe RM, 1998; 
Wilcox AJ et al, 1995). An excess of estrogens causes inhibition of cell proliferation in a dose-dependent 
manner in the male developing urethra (Yucel S et al, 2003). And exposure to synthetic estrogens during 
pregnancy induces hypospadias in a mouse model (Kim KS et al, 2004). These aspects indicate that 
estrogens, particularly through ESR2, have an important role in the normal and abnormal development of 
the male genitalia (Crescioli C, 2003).  
 
ENDOCRINE DISRUPTERS AND DISORDERS OF THE REPRODUCTIVE TRACT 
 
The hormonal dependence of masculinization renders this process inherently susceptible to disruption by 
factors that interfere with hormone production, bioavailability, metabolism or action (Gray LE Jr et al, 2004; 
Steinhardt GF, 2004). Several reports indicate that exposure to environmental toxicants, particularly those 
in the environment and in food, during pre- and post-natal development may be detrimental to the 
reproductive tract development and function. Examples are pesticides (DDT, methoxycholor, vinclozolin, 
trichlorfon, atrazine), plastics (phtalates), and a range of xenoestrogens, which directly or after being 
metabolized, act as endocrine disrupters, and elicit their actions on the developing reproductive structures 
(Hughes IA et al, 2006; Manson JM et al, 2003).  
 
Xenoestrogens and xenobiotics induce changes in the mRNA expression profile, as well as in the binding 
response, of estrogen receptors in developing reproductive structures (Thuillier R et al, 2003). Furthermore, 
estrogenic potency of phytoestrogens is significant, especially for ESR2, and they may trigger many of the 
biological responses that are evoked by the physiological estrogens (Kostelac D et al, 1993; Kuiper GG et al, 
1998).  
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Exposure to environmental components with estrogenic activity in utero induces a range of disorders of the 
male reproductive tract, such as lower sperm quality, cryptorchidism, hypospadias and testicular cancer 
(Bay K et al 2006, Delbes G et al, 2006). Boys born of women treated during their pregnancy with DES, a 
potent estrogenic compound indicated to prevent miscarriages, presented a higher rate of defects of the 
reproductive tract development. The most frequent structural and functional abnormalities reported were: 
epididymal cysts, meatal stenosis, microphallus, cryptorchidism and hypospadias (Klip HB et al 2002; Wilcox 
AJ et al, 1995). These findings were reproduced in laboratory animals, after the exposure to DES during 
fetal and neonatal live. Moreover, early transplacental administration of DES induces accelerated testicular 
development, abnormal differentiation of Sertoly cells, hyperplasia of fetal Leydig cells, and changes in the 
steroidogenic factor-1 in rats (Perez-Martinez C et al, 1996; Majdic G et al, 1997).  
 
Experiments in vitro and with animal models have indeed been very illustrative the negative effects of 
excessive estrogens on testicular development and functions (gametogenesis and steroidogenesis), which is 
essential to the proper masculinization of the male reproductive tract. Probably the most extreme case is in 
the marsupial tammar wallaby, in which high doses of estrogens can inhibit early testicular development, 
and testis determination, causing sex reversal (Coveney et al 2001).  
 
Although total sex reversal is not observed in mammals, estrogens can inhibit the development of 
gonocytes, Leydig and Sertoli cells in rat fetal testis (Lassurguere J et al, 2003). In mice, the spermatogenic 
lineage is able to independently respond to estrogens, where it induces ESR2-mediated inhibition of the 
development, and promotes apoptosis, of male germ cell line (Delbes G et al 2004). Moreover, lowered 
fertility rates are observed wildlife populations as a consequence of exposure to agents with estrogenic 
activity (Colborn T et al, 1993).  
 
Estrogens and estrogen-like chemicals can also disturb testicular steroidogenesis (Fukuzawa NH et al, 2003), 
and neonatal exposures induce disturbances of puberty onset (Atanassova N et al, 2000). Furthermore, high 
doses of estrogenic compounds during fetal life increase the risk to hypospadias and cryptorchidism in 
laboratory animals (reviewed by Sharpe RM, 2003). These evidences indicate processes which can be 
affected in mammal male reproduction by the exposure to environmental estrogens.  
 
The overall incidence of disorders of the male reproductive tract in newborns (hypospadias and 
cryptorchidism), young men (low sperm count and testicular cancer) and older men (prostate cancer), has 
increased, paralleling an increased exposure to endocrine disrupters (Baskin LS et al, 2001b; Bay K et al, 
2006), which suggests common etiological factors. It has been proposed that a maldevelopment of the fetal 
testis could underlie these disorders, comprising the testicular digenesis syndrome (TDT). The different 
steps of testis development may be disturbed to a greater or lesser extent by the exposure to endocrine 
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disruption, and result in digenesis, which will give rise to abnormal hormone production and trigger 
downstream aberrations of hormone dependent processes (Bay K et al, 2006; Delbes G et al, 2006).  
 
BALANCE BETWEEN ANDROGENS AND ESTROGENS 
 
Not only estrogens and androgens, but also the balance between the two is important to the development 
of the male genitalia. Estrogens modulate androgen levels and can inhibit testosterone production 
(Lassurguere J et al, 2003; Tsai-Morris CH et al, 1996). This modulation can occur at multiple levels, 
including the negative feedback exerted by estradiol on the hypothalamus-pituitary-gonadal axis (Gooren L, 
1989; Raven G et al, 2006); or the competition for the same binding protein (Joseph DR, 1994). 
Furthermore, an excess of estrogens alters the responsiveness to androgens, by down-regulation of AR by 
proteosome degradation pathway and by interfering with the Leydig cell function and testosterone 
production (Woodham C et al, 2003). 
 
The co-localization of ESRs and ARs in the developing male urethra and the evidence that estrogens and 
androgens have a direct effect on the fusion of the urethral folds (Yucel S et al, 2003), proposes that the 
urethral development depends on a delicate balance between these hormones (Aranda A et al, 2001; 
Sharpe RM et al, 2006). This hypothesis was circumstantiated by the prevention of the reproductive tract 
abnormalities induced in DES-treated in male rats when testosterone is co-administrated, demonstrating 
that the abnormalities induced by estrogenic compounds are, at least partially, a result of a disturbed 
androgen-estrogen balance (Rivas A et al, 2003). In addition, increased AR mRNA levels have been observed 
in male GTs as a response to in utero ethinyl estradiol exposure, possibly as an adaptive mechanism (Agras 
K et al, 2006). 
 
GENES VS ENVIRONMENT 
 
If environmental influences are detrimental to the regulation of the hormonal processes during 
development, ethnic – genetic - differences are also important in the susceptibility to environmental 
toxicants (Giwercman A et al, 2006; Nabholz CE, von Overbeck J, 2004). Interestingly, association with ESR2 
gene variants has been documented in some environmental sensitive male reproductive tract disorders, 
such as low sperm count (Aschim EL et al, 2005) and prostate cancer risk (Thellenberg-Karlsson C et al, 
2006) in Caucasians. Furthermore, gene variants in ESR2 gene may influence serum levels of testosterone, 
as individuals with longer (CA)n variants in this gene display lower serum androgen levels (Westberg L et al, 
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2001). These indications propound that variants in the ESR genes could also be involved in the etiology of 
hypospadias. 
 
ACTIVATING TRANSCRIPTION FACTOR 3, A HORMONE RESPONSIVE GENE 
 
Due to the importance of estrogens and ESRs in human reproduction and in urethral development, 
estrogen responsive genes can also be regarded as candidates for hypospadias. Indeed, gene profile from 
twin brothers with and without hypospadias, and comparison of microarray data of normal and hypospadic 
human tissue, evidence that the estrogen responsive genes ATF3, CTGF and Cyr61 are strongly up-regulated 
in hypospadiac tissue (Wang Z et al, 2007). These findings provide support for the concept that estrogenic 
responsive compounds have a role in the etiology of hypospadias and their up-regulation may correlate 
with an increased risk to this disorder of the urethral development.  
 
ATF3 is a member of the ATF/CREB (cAMP responsive element binding) family of transcription factors; it 
contains a basic region and leucine zipper (bZIP) motif characteristic of the bZIP superfamily of transcription 
factors, which includes members of the CCAAT/enhancer-binding protein family, the Jun/Fos family and 
ATF/CREB family (Fan F et al, 2002). Two main isoforms have been found for this gene. Isoform 1, the major 
and longest isoform, with 2049 bps represses rather than activates transcription from promoters with ATF 
binding elements. Isoform 2, also called deltaZip2, contains an additional exon in the 3' coding region, 
which includes a termination codon; this isoform lacks the leucine zipper protein-dimerization motif and it 
stimulates transcription presumably by sequestering inhibitory co-factors away from the promoter. It is 
possible that alternative splicing of the ATF3 gene may be physiologically important in the regulation of 
target gene (Chen BP et al, 1994).  
 
Recently, ATF3 started being studied in the context of sex development and hypospadias. These studies 
evidence that ATF3 expression is up-regulated during murine sexual differentiation and that, in GTs of 
estrogen-exposed mice fetuses, ATF3 mRNA levels are significantly increased (Liu B et al, 2006). 
Furthermore, Liu B et al, 2005, compared the expression of ATF3 in tissues from 28 children with 
hypospadias compared and in 20 normal penile skin tissue samples from elective circumcision. Eighty-six 
percent of the hypospadias samples were immunohistochemically positive, compared with only 13% of 
normal tissue samples. Moreover, 75% of hypospadias samples were positive from in situ hybridization, 
compared with 1% of circumcision samples. These findings indicate that ATF3 is up-regulated in the penile 
skin tissues of boys with hypospadias, and suggests a role for this transcription factor in the development of 
this abnormality. 
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AIMS 
 
 
 
I. TO ACCESS WHETHER GENE VARIANTS IN THE EARLY DEVELOPMENTAL GENES FGFR2, 
FGF8, FGF10 AND BMP7 CAN CAUSE OF HYPOSPADIAS 
 
II. TO INVESTIGATE IF THE ANDROGEN RECEPTOR’S CO-CHAPERONE FKBP52 IS INVOLVED IN 
THE ETIOLOGY OF HYPOSPADIAS 
 
III. TO EVALUATE THE ROLE OF THE ESTROGEN RECEPTOR GENES – ESR1 AND ESR2- IN 
HYPOSPADIAS 
 
IV. TO EXAMINE WHETHER ATF3, AN ESTROGEN REGULATED GENE, IS IMPLICATED IN 
HYPOSPADIAS 
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METHODS 
 
The protocols for the research project have been approved by the Ethics Committee of the institutions 
where the work was undertaken; and it conforms to the provisions of the Declaration of Helsinki in 1995 (as 
revised in Edinburgh 2000). Subjects and/or their parents gave informed consent and patient anonymity 
has been preserved. 
 
PATIENTS AND CONTROLS 
 
For sequence analysis, DNA from boys with non-syndromic hypospadias of different severities, both familial 
and sporadic cases, and of both Swedish and non-Swedish ethnicities, selected through medical records in 
Sweden, was analyzed. As control group we used DNA from an anonymous sample constituted of 380 
healthy voluntary blood donors at Karolinska University Hospital, Sweden. Genomic DNA was extracted 
from EDTA-preserved blood, using standard protocols. 
 
For expression analysis, human foreskin samples from prepubertal boys were obtained after surgery at the 
Karolinska University Hospital. The samples were prepared according to standard procedures. Through 
collaboration with the Department of Pediatric Urology at the University of Innsbruck, Austria, fetal 
samples, obtained following miscarriage, with no signs of maceration or macroscopic abnormality were 
studied. The age of the fetuses was estimated from crown-rump length, as defined by standard protocols. 
The ano-genital structures were removed en bloc from fresh fetuses and fixed in formalin. The specimens 
were routinely embedded in paraffin, processed into 4 μm serial transverse sections and dried at 60ºC 
overnight. 
 
DNA ANALYSIS 
 
PCR 
 
Polymerase chain reaction (PCR) is an enzyme-mediated reaction which is used to amplify the number of 
copies of a specific region of DNA, in order to produce enough DNA to be adequately tested. Optimized PCR 
protocols were used: DNA to be amplified has been put in solution with short DNA primers which bind to 
the 3' ends of the DNA, the 4 nucleotide bases (dNTPs), magnesium chloride, DMSO as needed; and DNA 
polymerase. In our experiments high-fidelity DNA polymerases working at very high temperature were 
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used: AmpliTaq Gold®, Applied Biosystems; and Finnzymes - DyNAzyme™ EXT DNA Polymerase, which 
contains a proofreading enzyme. Normally, about 30 cycles of amplification are carried out, each with 
three steps 1) DNA is heated to 95o C – the double-stranded DNA denatures; 2) the solution is then cooled 
to 55o -64o C - primer annealing to template DNA; 3) and then the temperature is raised to 72o and the DNA 
polymerase causes the synthesis of new complementary single strands in solution - primer extension. The 
cycling process of PCR is automated and completed in a few hours in a thermocycler. In 30 cycles at 100% 
efficiency, close to 1 billion copies of targeted DNA region are created.  
 
PCR was carried out in 96 or 384 wells plates, in total volumes of 25 and 5 µl respectively; and blank 
controls were added (water instead of genomic material) as contamination control.  
 
DHPLC WAVE 
 
Denaturing high-performance liquid chromatography (DHPLC) -WAVE was used for mutation detection and 
SNP discovery. It is an automated and high-throughput method. The principle of DHLPC’s fragment 
separation lies in the ability to separate two or more chromosomes as a mixture of previously denatured 
and reannealed PCR amplicons, revealing the presence of a mutation by the differential retention of homo- 
and heteroduplex. DHPLC was carried out on an automated WAVE instrument equipped with a DNASep 
column (Transgenomic Inc., Omaha, NE). Column temperature was selected for optimal heteroduplex 
separation, using the WAVERMAKER 3.4 software.  
 
Temperature determines sensitivity; and its optimum for each DNA fragment has been predicted by 
computation. The DNA is eluted from the column as an increasing concentration of acetonitrile flows across 
the matrix. Heteroduplexes formed in heterozygous samples will elute before homoduplexes, appearing as 
two or more peaks in electropherograms, instead of only one. Single-nucleotide substitutions, deletions, 
and insertions have been detected successfully by on-line UV or fluorescence monitoring within 2-3 
minutes in unpurified amplicons as large as 1.5 Kb. Sensitivity and specificity of DHPLC consistently exceed 
96%. (Xiao W et al, 2001).  
 
DHPLC was carried out on an automated WAVE instrument equipped with a DNASep column (Transgenomic 
Inc., Omaha, NE). Column temperature was selected for optimal heteroduplex separation, using 
WAVERMAKER 3.4 software. The reactions were carried out in 96 well plates, and each well contained 
denaturated PCR product. Direct sequence analysis was used to confirm DHPLC results.  
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SEQUENCING 
 
Direct capillary DNA sequencing of PCR products became the method of choice for sequence analysis, 
allowing unambiguous identification the target sequence, the detection of allele variants and mutations, 
resolution of difficult heterozygous combinations, and recognition of new alleles. Direct sequencing was 
performed using BigDye Terminator v3.1. sequencing kit (Applied Biosystems Foster City, CA). This method 
essentially involves amplifying a single stranded piece of DNA many times. Normally, when DNA is 
amplified, new deoxy-nucleotides (dNTPs) are added as the strand of DNA grows. Special bases called 
dideoxy-nucleotides (ddNTPs) are added to the reaction. These are similar to dNTPs, except for two 
important differences: they have fluorescent tags attached to them (a different tag for each of the 4 
ddNTPs) and are missing a crucial atom that prevents new bases from being added to a DNA strand after a 
ddNTPs has been added. Thus, once a ddNTP is inserted into a growing DNA strand, synthesis of that strand 
is stopped (BigDye Terminators). After many repeated cycles of amplification, all the possible lengths of 
DNA are represented and every piece of synthesized DNA containing a fluorescent label at its terminus.  
 
To increase the sequencing quality, PCR product cleaning was performed before every sequence reaction 
using ExoSAP-IT, which removes any unconsumed dNTPs and primers remaining in the PCR mixture by 
utilizing two hydrolytic enzymes, exonuclease I and shrimp alkaline phosophatase. Thereafter, sequencing 
reaction was carried out in 96 well plates, each with 2μl of cleaned PCR product and 3pmol of the 
sequencing primer were used in a 20μl sequencing reaction. The sequencing reaction mixes were subjected 
to 25 cycles in a thermal cycler. Each cycle consisted of 10’’ 95°C, 5’’ 50°C and 4’ 60°C. Capillary sequencing 
was performed in ABI Prism 3730 Sequencer (PE Applied Biosystems,), with post analysis with the program 
SeqScape v2.5 (Applied Biossystems). The primers used for sequencing were the same as for the PCR 
reaction; and bidirectional sequencing was performed. 
 
SIZE FRAGMENT ANALYSIS 
 
Microsatellites (sometimes referred to as a variable number of tandem repeats or VNTRs) are short 
segments of DNA that have a repeated sequence, such as (CA)n and (TA)n in ESRs, found in most genomes; 
and they tend to occur in non-coding DNA. These polymorphisms show exceptional variability, making 
them the genetic marker of choice for the number of applications, including the analysis of genetic 
structure and parentage testing, and to investigate evolutionary links between species and populations. 
Microsatellites are particularly useful as markers in genetic mapping. 
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Microsatellite analysis was carried out by PCR amplification of the microsatellite loci, using fluorescently 
labeled primers; followed by analysis detection of the alleles according to size (Dearlove AM, 2002) on an 
ABI Prism 3730 Analyzer, a capillary electrophoresis platform that provides accurate size calling, consistent 
band intensities and lower run-to-run migration variations than ever before. The Applied BioSystems 3730 
DNA Analyzer has the ability to determine the size of DNA fragments by using a fluorescence-based 
detection system. As the DNA migrates through the detection cell, the 48 capillaries are simultaneously 
illuminated from both sides of the array by an argon-ion laser. A fluorescent size standard in each capillary 
eliminates variability. The fluorescent emissions are spectrally separated by a spectrograph and focused 
onto a charged couple device, which are then converted to digital information that is processed by the 
collection software, the GeneMapper™ Version 3.7 software. The reactions were carried out in 96 well 
plates, and each well contained 1µl of PCR product, 0.5µl of size standard and filled to 10µl with hi-Di 
formamide. 
 
SNP TYPING/ ALLELE DISCRIMINATION BY TAQMAN 
 
Allelic discrimination using the TaqMan 5' Nuclease Assay with fluorogenic probes provides a rapid and 
sensitive method for detecting known mutations or polymorphisms. This method combines PCR and 
mutation detection in a single step. A hybridization probe is cleaved by the 5' nuclease activity of Taq DNA 
polymerase only if the specific sequence is successfully amplified. Two TaqMan (PE Applied Biosystems) 
probes are used, one for each allele. Each probe consists of an oligonucleotide with a 5' reporter dye and a 
3' quencher dye. The reporter dyes used are FAM and VIC; and TAMRA is used as the quencher dye. 
Initially, the proximity of the quencher suppresses the fluorescent signal given by the reporter. The TaqMan 
probe hybridizes to a smaller 20- to 24mer sequence, which includes the polymorphism. AmpliTaq Gold (PE 
Applied Biosystems) enzyme then cleaves the probe with its 5'-3' nuclease activity. Thus, the reporter dye 
and quencher dye become separated, causing an increase in the fluorescence intensity of the reporter dye. 
This florescence can then be detected to discriminate the alleles of each sample. If there is fluorescence 
from the VIC reporter for the wild-type allele, then the sample is typed as a homozygous for the wild-type 
allele; fluorescence from only the FAM reporter represents the homozygosity for the mutant allele; 
intermediate fluorescence from both reporters represents the heterozygous population (Shi MM, 2002). 
Reactions were conducted using standard protocols in 384 well plates. 
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EXPRESSION ANALYSIS 
 
IMMUNOHISTOCHEMISTRY  
 
IHC is a widely used method to localize proteins in cells of a tissue section, exploiting the principle of 
antibodies binding specifically to antigens in biological tissues. Visualizing an antibody-antigen interaction 
can be accomplished in a number of ways. In the most common instance, an antibody is conjugated to an 
enzyme, such as peroxidase, that can catalyze a color-producing reaction. Alternatively, the antibody can 
also be tagged to a fluorophore, such as FITC, rhodamine, or Texas Red. 
 
DIRECT AND INDIRECT IMMUNOHISTOCHEMISTRY  
 
There are two strategies used for the immunohistochemical detection of antigens in tissue, the direct 
method and the indirect method. The direct method is a one-step staining method, and involves a labeled 
antibody reacting directly with the antigen in tissue sections. While the procedure is simple and rapid, it is 
in less common use than indirect methods because it can suffer problems with sensitivity due to little signal 
amplification.  
 
The indirect method, used in the ATF3 and FKBP52 studies, involves an unlabeled primary antibody (first 
layer) which reacts with tissue antigen, and a labeled secondary antibody (second layer) which reacts with 
the primary antibody. (The secondary antibody must be against the IgG of the animal species in which the 
primary antibody has been made). This method is more sensitive due to signal amplification through 
several secondary antibody reactions with different antigenic sites on the primary antibody. The second 
layer antibody can be labeled with a fluorescent dye or an enzyme. 
 
ANTIBODIES 
 
The antibodies used in the ATF3 and FKBP52 studies were polyclonal antibodies, obtained commercially. 
Polyclonal antibodies are made by injection of animals with peptide antigens together with an immuno-
stimulus, after which antibodies from whole serum can be isolated. Thus, polyclonal antibodies are a 
heterogeneous mix of antibodies that recognize several epitopes of the same protein.  
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TISSUE PREPARATION  
 
Genital foreskin samples obtained after surgery and genital fetal tissue recovered following miscarriage, 
were analyzed for FKBP52 or for ATF-3 expression. In the case of FKBP52, human prostate was used as 
positive control. Prostate tissue was obtained from a patient surgically treated for benign prostatic 
hyperplasia. The tissues were fixed for 5 to 7 hours in 4% formalin, washed 10 minutes in PBS four times 
and kept in 70% EtOH until paraffin embedding.  
 
PROCEDURE 
 
The paraffin sections were dewaxed, rehydrated and treated for antigen retrieval by heating at 98°C in 
0.1M Tris ph 9.0 for 20 minutes. The slides were allowed to cool to room temperature. Endogenous 
peroxidase activity was blocked by treating the sections with 1M H2O2 for 15 minutes in dark. To block 
nonspecific antibody binding, sections were pre-incubated in 10mg/ml BSA (Sigma) containing 10% goat 
non-immune serum (Vector) for 40 min. Affinity-purified polyclonal anti-FKBP52/ anti-ATF-3 was applied to 
the sections at a 1:100 dilution in 10mg/ml BSA and allowed to incubate at 4°C overnight in a humid 
chamber. Control sections were incubated without primary antibody. The sections were incubated with the 
biotinylated secondary goat anti rabbit antibody (Vector) diluted in buffer containing 1% BSA and 10% goat 
serum followed by enzyme conjugate application (ABC, Vector) and chromogen development (AEC, Vector). 
All sections were counterstained with hematoxylin (Merck) for 15 sec before mounting in Kaiser’s glycerin 
gelatin (Merck). Images of immune-stained tissues were captured using a Zeiss microscope. Background 
controls were performed similarly using only the secondary antibody. 
 
GENOTYPING AND GENETIC STATISTICS  
 
POLYMORPHISMS SELECTION  
 
In the study of FKBP52, two SNPs in the FKBP4 gene were selected from the dbSNP Homepage at NCBI: 1) 
the SNP rs1062478 (His> Arg), the only non synonymous polymorphism in the gene with known frequency 
(heterozygozity of 0.039); and 2) the intronic SNP rs3021522 (C>G) (heterozygozity of 0.109), the only 
polymorphism that was found by sequencing among the initially 91 screened patients. In the ESR2 gene, 
four haplotype-tagging SNPs from the dbSNP database (htSNP: rs2987983, rs1887994, rs1256040, and 
rs1256062) have been chosen, as they capture 99.6% of the haplotype variation in the Swedish population 
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(Thellenberg-Karlsson C et al, 2006). Two additional SNPs (rs10483774 and rs1271572) were added, since 
they map to a region of predicted intense transcription factor binding in the putative promoter region. The 
(CA)n repeat polymorphism was also included in this study. In ATF3, eight haplotype-tagging SNPs were 
selected from the dbSNP Homepage at NCBI using a tagger SNP software, Haploview version 3.32 (Barret et 
al, 2005), with the HapMap data for Caucasian population data, with a LOD cut-off can of 2.0 and a r2 >0.8, 
including SNPs with a minor allele frequency of 2% (Table 2).  
 
GENOTYPING 
 
SNP typing was performed with a 5'-nuclease TaqMan assay together with fluorescently labeled probes 
using standard protocols (Applied Biosystems). The samples were analyzed on an ABI 7900HT. The lengths 
of the (CA)n repeat were analyzed in an ABI 3730 DNA analyzer (Applied Biosystems). The lengths of the 
(CA)n containing fragments were ascertained by two different PCRs.  
 
STATISTIC ANALYSIS 
 
After DNA analysis, genotyping quality was tested by checking the conformance with Hardy–Weinberg 
equilibrium with Haploview version 3.32 (Barret et al, 2005). All gene variants were in Hardy–Weinberg 
equilibrium. 
 
To identify potentially associated polymorphisms, we performed global tests of allele and genotype 
frequency differences among the cases and the controls. We initially performed χ2 and Fisher exact tests. 
Odds ratios (OR) and OR’s 95% confidence intervals (OR 95% CI) were estimated. The analysis was 
conducted using standard statistic packages. Further single locus and multi-marker haplotype association 
tests were performed with two different softwares, Haploview (Barret et al, 2005) version 3.32 and 
Unphased (Dudbridge F, 2003) version 3.0.3, thus providing complementary validity to our results. The 
calculations were performed both with and without missing data estimation. The threshold for rare 
haplotypes frequency identification was 0.005. The p-values were corrected for multiple testing by 
performing permutations as follows: The trait values were randomly shuffled between subjects 1000 times. 
In each permutation the minimum p-value is compared to the minimum p-value observed in all the 
analyses in the original dataset. Pair wise linkage disequilibrium (LD) between polymorphisms was 
measured by estimating D’, (the normalized disequilibrium coefficient, which ranges from 0 to 1); and the 
squared correlation coefficient r2. Hardy–Weinberg (HW) equilibrium of the genotype frequencies at each 
SNP in controls and cases was accessed with Haploview version 3.32.  
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To determine whether the associated risk gene variants were independent, logistic regression analysis was 
performed on the SAS computer program (SAS Institute Inc, Cary, NC) where the proc logistic command 
was used. This resulted in a standard logistic regression model in which the regression coefficients were 
logarithms of the odd ratios. Models were compared using the log likelihood ratio test which approximates 
to a χ2 distribution with 1 df (the difference in number of factors in the models). Initially, different genetic 
models for each marker against each other were tested (dominant, recessive and co-dominant models). 
The analysis presented in the table 4 only includes data for the best model (co-dominant). In order to get 
OR estimates for the different genotypes, variables were re-coded into design variables. 
 
BIOINFORMATICS AND COMPUTATIONAL BIOLOGY 
 
Bioinformatics and computational biology are multidisciplinary subjects that integrate information and 
computer technology with biotechnology and biological sciences. The main functions of these tools consist 
in the recording, annotation, storage, and search/retrieve of nucleic acid sequence (genes and RNAs), 
protein sequence and structural information; as well as to provide reliable computational interpretation of 
a wide range of experimental data, and the detailed understanding of the molecular apparatus behind 
cellular mechanisms of sequence information.  
 
These tools were of great importance for this work: for sequence identification; to design primers; to 
predict the function and structure of proteins and to investigate how sequence variants could change that 
function and structure; to predict the promoter sequences, and to identify transcription factor binding 
spots; to compare the sequence of different organisms and to calculate the homology between those 
sequences; to search for known mutations in the gene; to analyze data or consult and retrieve biological 
information. For each task, different databases and bioinformatics resources were used, in order to obtain 
a more accurate prediction. 
 
The next paragraphs present a brief description of the used genetic databases and of the available 
bioinformatics and computational tools. 
 
GENETIC DATABASES 
 
A biological database is a large, organized body of persistent data, usually associated with computerized 
software designed to update, query, and retrieve components of the data stored within the system. As an 
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easy method to access to the information, it became an essential resource for life sciences. Different 
databases serve different purposes.  
 
PRIMARY DATABASES 
 
Primary databases are the primary data repositories, usually type specific (e.g. sequence, microarray data, 
SNPs), freely available to the community. The data is usually not deeply integrated with other biological 
knowledge or attributes. Examples of these databases are: 
 
- The GDB Human Genome Database is the official central repository for genomic mapping data resulting 
from the Human Genome Initiative. 
- GenBank: The National Institutes of Health (NIH)’s genetic sequence database, an annotated collection 
of all publicly available DNA sequences  
- EMBL: The European Molecular Biology Laboratory Nucleotide Sequence Data Library constitutes 
Europe's primary nucleotide sequence resource. Main sources for DNA and RNA sequences are direct 
submissions from individual researchers, genome sequencing projects and patent applications. 
 
CURATED DATABASES 
 
Curated databases are derivative databases, which often provide added value to data from repositories by 
eliminating redundancy, providing standard nomenclature, and often serving specific research 
communities. Examples of these databases are: 
 
- NCBI: The National Centre for Biotechnology Information created a public database, with access to 
multiple resources: OMIM, Human Genome Resources, Entrez Gene, Search BLAST using Sequence data, 
BLAST against mouse trace data, Search PubMed, Search Nucleotide Database, Search Protein Database, 
Unigene Database, as well as other. Its Reference Sequence (RefSeq) collection is of particular interest 
as it provides a comprehensive, integrated, non-redundant set of sequences, including genomic DNA, 
transcript (RNA), and protein products, for major research organisms. 
- SWISS-PROT/TrEMBL: The SWISS-PROT database contains high-quality annotation, is non-redundant 
and cross-referenced to many other databases. Together with UniProtKB/TrEMBL, it constitutes the 
UniProt Knowledgebase, one component of the Universal Protein Resource (UniProt), allowing easy 
access to all publicly available information about protein sequences. It links to the Expert Protein 
Analysis System (ExPASy). 
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- PDB-Protein Data Bank: Provides a variety of tools and resources for studying the structures, 
determined by X-ray crystallography and NMR, of biological macromolecules and their relationships This 
site offers tools for browsing, searching, and reporting that utilize the data resulting from ongoing 
efforts to create a more consistent and comprehensive archive. 
- MGI: The Mouse Genome Informatics provides integrated access to data on the genetics, genomics, and 
biology of the laboratory mouse. 
 
GENOME BROWSERS 
 
Genome browsers are another type of databases, designed for graphical display of genome content; and to 
relate genome data from multiple sources. Examples of these databases are: 
 
- ENSEMBL: A joint project between EMBL- European Bioinformatics Institute (EBI) and the Wellcome 
Trust Sanger Institute (WTSI) to develop a software system which produces and maintains automatic 
annotation on selected eukaryotic genomes. The Ensembl project provides accurate, automatic analysis 
of genome data.  
- UCSC Genome Browser: This site contains the reference sequence and working draft assemblies for a 
large collection of genomes. This tool has a number of very useful features. The Genome Browser zooms 
and scrolls over chromosomes, showing the work of annotators worldwide. The Gene Sorter shows 
expression, homology and other information on groups of genes that can be related in many ways. Blat 
quickly maps your sequence to the genome. The Table Browser provides convenient access to the 
underlying database. VisiGene provides a large collection of in situ mouse and frog images to examine 
expression patterns. Genome Graphs allows to upload and display genome-wide data sets. 
 
SHIFTED DATABASES 
 
Another type of databases is the shifted databases, which combine information from different highly 
curated databases into new views of the data or biological knowledge. The best well known examples are 
the:  
 
- GeneCards, an integrated database of human genes that includes automatically-mined genomic, 
proteomic and transcriptomic information, as well as orthologies, disease relationships, SNPs, gene 
expression, gene function, and service links for ordering assays and antibodies.; from the Weismann 
Institute of Science, Rehovot, Israel. 
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- GENATLAS gene databases, contains relevant information with respect to gene mapping and genetic 
diseases. The application is developed and maintained at the Paris René Descartes University, Paris, 
centre of bioinformatics. GENATLAS is structured in three databases: Genes database, Phenotypes 
database, Citations database. Information about a gene/ protein/ phenotype is links to other databases, 
such as NCBI and ENSEMBL. 
 
COMPUTATIONAL BIOLOGY TOOLS 
 
A large range of bioinformatic tools are available freely online. The most commonly used tools in this thesis 
work are presented below. 
 
SEQUENCE ANALYSIS AND STRUCTURE PREDICTION TOOLS  
 
- BCM search launcher: The Baylor College of Medicine Search Launcher is an on-going project to 
organize molecular biology-related search and analysis services available on the WWW with a single 
point-of-entry for related searches. It provides several tools, such as multiple sequence alignment, 
molecular biology-related search and analysis services on the web. 
- CBS Prediction Servers: Provided by the Centre for Biological Sequence Analysis at the Technical 
University of Denmark, includes whole genome visualization and analysis, gene finding and splice sites, 
analysis of DNA microarray data, protein sorting, post-translational modifications, immunological 
features, protein function and structure 
- ExPASy-Tools: The ExPASy (Expert Protein Analysis System) proteomics server of the Swiss Institute of 
Bioinformatics (SIB) is dedicated to the analysis of protein sequences and structures. It performs DNA to 
Protein similarity searches, protein identification and characterization, topology prediction, post-
translational modification prediction, protein structure analysis (Incl. PHRYE), sequence alignments and 
phylogenetic analysis. 
 
PROMOTER AND SPLICING PREDICTION AND ANALYSIS PROGRAMS  
 
- RAVEN- Regulatory analysis of Variation in Enhancers: Created at CGB, Karolinska Instituted, RAVEN 
search for putative regulatory genetic variation in selected genes. SNPs (from dbSNP and user defined) 
are analyzed for overlap with potential transcription factor binding sites and phylogenetic foot printing 
using human and mouse sequences.  
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- GeneID- gene prediction tools: a program from the Grup de Recerca en Informàtica Biomèdica  
Universitat Pompeu Fabra, Barcelona, that predict genes in anonymous genomic sequences designed 
with a hierarchical structure. 
- NNSPLICE: splice site prediction through the analysis of the structure of donor and acceptor sites using a 
separate neural network recognizer for each site. Accessible at Berkeley Drosophila Genome Project 
web page. 
- Genscan: Developed GENSCAN was developed in the Department of Mathematics, Stanford University, 
predicts exon-intron structures of genes in several organisms. 
- Primer3: A widely used program for designing PCR primers, developed at Whitehead Institute and 
Howard Hughes Medical Institute, many different input parameters and options that can be controlled. 
 
HOMOLOGY PREDICTION 
 
- HomoloGene: One of NCBI’s resources; it offers a system for automated detection of homologues 
among the annotated genes of several completely sequenced eukaryotic genomes. 
- ClustalW: Produces biologically meaningful multiple sequence alignments of divergent sequences. It 
calculates the best match for the selected sequences, and lines them up so that the identities, 
similarities and differences can be seen. Evolutionary relationships can be seen via viewing Cladograms 
or Phylograms. 
 
SNP SEARCH AND ASSOCIATION STUDIES SETUP 
 
- Genetic Association Database: An archive of human genetic association studies of complex diseases and 
disorders.  
- dbSNP: public-domain archive for a broad collection of simple genetic polymorphism, incorporated into 
NCBI's system. 
- HGVbase: Provides an accurate, high utility and fully comprehensive catalogue of normal human gene 
and genome variation, useful as a research tool to help define the genetic component of human 
phenotypic variation. All records are curated and annotated, ensuring maximal utility and data accuracy. 
- HapMap: all processed data from the HapMap project.  
- Packages for deriving haplotype tagging SNPs: Haploview, SNPtagger, ClusTag, HapBlock, htSNP, 
htSNPer, Tagntell. 
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RESULTS 
 
In order to explore each one of the aims of this thesis, a series of analysis were performed. In this section, 
the results of these analyses are presented. 
 
I. STUDY OF FGFR2, FGF8, FGF10 AND BMP7 IN BOYS WITH HYPOSPADIAS  
 
The analysis of the DNA from 60 patients with non-syndromic familial hypospadias, of different severities, 
revealed several gene variants in the FGF8 and FGFR2 genes (Figure 6). 
 
 
 
Figure 6: Gene variants in FGF8 and FGFR2 detected in our hypospadias patients. 
 
 
The analysis of the FGF8 sequence (NM_033164; Ensembl Transcript ID: ENST00000344255) revealed, in 4 
Swedish patients, two heterozygous sequence variants in the segment constituted by the exon 6 and 
adjacent intronic sequences. Three of those boys presented the polymorphism rs3218238 (c.582-
62G>A/IVS6-62G>A). This polymorphism was not detected in a control population of 96 individuals, thus 
resulting in a statistically significant difference. Another patient of Swedish origin presented a synonymous 
c.590C>G sequence variant, which was not present among controls. This gene variation may represent a 
private mutation. 
 
Analysis of the FGFR2 (NM_022976, Ensembl Transcript ID: ENST00000358487) sequence revealed several 
single nucleotide variations found in Swedish patients: rs755793 (p.Met186Thr), c.382+52->G (IVS2+52->G), 
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c.550+27 C>T (IVS3+27C>T), c.727+180 T>G (IVS4+180 T>G) and c.2454C>T. None of them were found in 
the control population. The FGFR2 gene variant c.727+180 T>G (IVS4+180 T>G) was present in 3 non-
related boys (P<0,05). The variants c.382+52->G, c.550+27C>T, and c.2454C>T, found uniquely in unrelated 
boys, may represent private mutations. None of these sequence variants is predicted to cause any splicing 
alteration or protein structure modifications by the previously mentioned methods. Other gene variants 
were found in this gene: rs1047100, rs4647915, rs1047101, rs3135802, rs1613776, rs3135806 and 
c.2575+15C>T (IVS17+15C>T); but all are in the same frequency as the control population.  
 
The SNP c.830T>C, which converts the amino acid 186 from a hydrophobic (Methionine) to hydrophilic 
(Threonine) amino acid, was the only non-synonymous polymorphism found in FGFR2 in our cohort. The 
affected patient presented a mid-penile type of hypospadias. This gene variant is located in the Ig-like C2-
type 1 extracellular domain of the protein (UniProtKB/Swiss-Prot entry P21802), a crucial element to ligand 
binding functions. However, neither homology nor protein structure predictions suggest any functional 
implications of this gene variant. 
 
No sequence variants were found in BMP7 or in FGF10.  
 
II. ANALYSIS OF THE FKBP4 SEQUENCE AND EXPRESSION IN HYPOSPADIAS 
 
SEQUENCE ANALYSIS 
 
The 10 exons and intronic/exonic borders of FKBP4 (NM_002014.2, Ensembl Transcript ID: 
ENSP00000001008), were bi-directionally sequenced in 93 boys with hypospadias, both sporadic and 
familial cases, from different ethnical groups, and with several phenotypic severities. No mutation was 
found. The intronic sequence variation rs3021522 (c.915C > G), in intron 6, was detected in five boys with 
hypospadias. 
 
Typing of rs3021522 was performed in 333 (including the initial 91) non-syndromic hypospadias patients 
and 380 controls. The SNP rs1062478, which converts the aminoacid Histidine, a polar and weakly basic 
aminoacid, into Arginine, a polar and strongly basic aminoacid, and the only reported non-synonymous SNP 
in this gene, was also typed in the same case and control groups. Genotyping yielded a 95% success rate. 
Analysis of allele and genotype frequencies in cases and controls evidenced no genotype and allele 
frequency differences between the two groups. 
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IMMUNOHISTOCHEMISTRY 
 
We looked at the expression of FKBP52 in human penile foreskin from hypospadias patients and controls 
(operated for circumcision). As in the mice, FKBP52 shows expression in luminal epithelial cells of human 
prostate, which was used as positive control. 
 
FKBP52 immuno-staining is observed in the epidermis of prepubertal male genital foreskin. Some staining is 
also observed in cells in the dermis, mostly consisting of fibroblasts and smaller blood vessels. Similar to the 
prostate where FKBP52 and AR are co-expressed in luminal epithelial cells, AR is also observed in the 
epidermal region of the foreskin, mostly localized to nuclei whereas FKBP52 staining is predominantly 
cytoplasmic. We could not observe any apparent differences in the level of FKBP52 staining between mild 
or severe hypospadias patients. Besides, the healthy control individuals show similar pattern and intensity 
of FKBP52 expression in the epidermal and dermal region. 
 
III. EVALUATION OF THE ESTROGEN RECEPTOR GENES-ESR1 AND ESR2-IN HYPOSPADIAS 
 
MUTATION SCREENING IN ESR1  
 
No coding mutations were found in a set of 60 boys with hypospadias in ESR1 (NM_000125.2, Ensembl 
Transcript ID: ENST00000206249). The SNP rs1801132 (1337G>C), located in exon 4, was detected in this 
patients’ group; this SNP was typed in 30 additional patients and a control population of 96 healthy 
individuals. The heterozygozity was 0.44 in patients and 0.46 in controls, similarly to data published in the 
public databases. No significant different was detected between cases and controls (X2=0; p>0,05).  
 
(TA)N IN ESR1  
 
Forty-five patients and forty-five controls were analyzed. The two groups have normal distribution and 
similar variances. The length of the segment containing the (TA)n repeat polymorphism in ESR1 ranged 
from 181 to 217 base-pairs, and no statistical difference was found between the two groups (T tested for 
paired samples; normal distribution verified; P>0,05). The results were similar to those published by 
Westberg et al, 2001.  
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MUTATION SCREENING IN ESR2  
 
No coding mutations were found in ESR2 (NM_001437.2, Ensembl Transcript ID: ENST00000341099), in a 
same set of 60 boys with hypospadias. However, a sequence variation rs944050 in the 4th base pair 
upstream of exon 9 was detected in 3 unrelated boys. Therefore 30 additional patients were analyzed, 
together with a control population of 96 individuals. Among the 90 tested patients, the sequence variation 
was found in six individuals with a familial type of hypospadias, five from Sweden and one of Iranian origin. 
Three of them had moderate to severe hypospadias; the other three presented a mild, glandular 
hypospadias. Only one individual from the control population presented this variation (P<0,05).  
 
(CA)N IN ESR2 
 
Forty-five patients and forty-five controls were analyzed. The two groups have normal distribution and 
similar variances. The patients’ group present longer alleles than controls (Figure 7: T-test for paired 
samples; normal distribution verified; P<0,05).  
 
FURTHER STUDIES ON ESR2 
 
To clarify the effect of ESR2 gene variants on the risk to hypospadias, the genotypes from 354 boys with 
non-syndromic hypospadias and 380 healthy voluntary blood donors was analyzed. Initially, 4 haplotype 
tagging SNPs, rs2987983, rs1887994, rs1256040, rs1256062 (Thellenberg-Karlsson C et al, 2006) and the 
(CA)n repeat polymorphism were typed. All loci were in HWE. Single marker analysis revealed significant 
association with the SNP rs2987983 (p<0.01), in the putative promoter region. And association with the 
(CA)n repeat polymorphism (p<0.02), in intron 6 was confirmed. The estimated p-values after correction for 
multiple comparisons with 1000 permutations remain below 0.05.  
 
The comparison of (CA)n lengths in patients and controls, with a T-test assuming equal variances, 
confirmed that longer variants are more common in patients (Figure 8), yielding a p-value < 0.002. Using 
the fragment length of 159 bp (Westberg L et al, 2001) as threshold above which a fragment is considered 
long (fragments <159bp S= short; fragments ≥159bp L= long), the L allele is more common among patients 
than in controls, with an OR of 1.43 (OR 95% CI 1.1-1.8), p<0.004. The comparison of SS vs SL vs LL genotype 
frequencies of the (CA)n polymorphism in patients and controls reveals that the LL genotype is more 
common among patients than controls with an OR for the LL genotype of 1.48 (OR 95% CI 1.1-2.0), p<0.02. 
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Figure 7: Initial ESR2 study: Distribution on (CA)n length across the patients and controls (Controls: N = 45, Mean: 
156,4; Patients: N = 45, Mean: 158,8). T value assuming equal variances: 2,873 (confidence interval of 95%); p 
value<0,01.  
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Figure 8: Further studies on ESR2: Distribution on (CA)n length across the patients and controls (Controls: N = 380, 
Mean: 158.9; Patients: N = 354, Mean: 159.7). T value assuming equal variances = -3; p<0.002.  
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MARKER PATIENTS VS CONTROLS Statistics 
 
ALLELES GENOTYPES 
 
RS2987983 
 T C TT CT CC p-VALUE <0.01 
OR (CC) 1.96 
(OR 95% CI 1.2-3.1) 
P 435 261 142 151 55 
C 526 228 182 162 33 
 
RS10483774 
 A G AA AG GG p-VALUE <0.01 
OR (AG) 7.47 
(OR 95% CI 2.1-27) 
P 671 13 329 13 0 
C 756 2 378 2 0 
 
RS1271572 
 G T GG GT TT  
N.S. P 370 288 107 156 66 
C 401 355 106 189 83 
 
RS1887994 
 G T GG GT TT  
N.S. P 611 53 279 53 O 
C 683 59 312 59 4 
 
RS1256040 
 T C TT TC CC  
N.S. P 676 293 105 151 71 
C 414 342 112 190 76 
 
(CA)N 
 S L SS SL LL p-VALUE <0.02 
OR (LL) 1.48 
(OR 95% CI 1.1-2.0) 
P 170 510 20 130 196 
C 241 505 43 155 175 
 
RS1256062 
 A G AA AG GG  
N.S. P 589 99 258 73 13 
C 658 100 286 86 7 
Table 2: Patients (P) vs. Controls (C) study for single locus analysis: Three of the studied polymorphisms in ESR2 
associated with hypospadias: the C allele and the CC genotype in rs2987983, in the ESR2 promoter; the G allele and 
the AG genotype in rs10483774, in ESR2 promoter; and longer (CA)n in intron 6. The estimated p-value after 
correcting for multiple comparisons by performing 1000 permutations remains below 0.05. NS= Not significant. 
 
 
The C allele and the CC genotype in the promoter SNP rs2987983 are associated with hypospadias, with an 
OR of 1.38 (OR 95% CI 1.1-1.7) and of 1.96 (OR 95% CI 1.2-3.1) respectively, yielding p-values < 0.01 (Table 
2). To further study the promoter region, we performed analysis to detect SNPs that affect transcription 
factor binding sites. The analysis revealed that the SNP rs2987983 is located in a region of intense 
transcription factor binding, mapping to two other SNPs, rs1271572 and rs10483774. We typed these two 
additional SNPs, and observed that the G allele of rs10483774 in the ESR2 promoter is also associated to 
hypospadias with an OR for the AG genotype of 7.47 (95% CI 2.1-26.8), p<0.01. However, this SNP is very 
uncommon and therefore much less informative than SNP rs2987983. Since the two are in LD (D’ of 1), we 
focused our analysis on the latter. No association was found with the SNP rs1271572.  
 
Global D’ for all tested polymorphisms is 0.846. This high value is mostly due to a high LD between the SNPs 
rs2987983 and rs1256040, defining an approximately 1700 bp long haplotype block. LD is much lower to 
and between the remaining SNPs. D’ between rs2987983 and (CA)n is low (0.35), indicating that these two 
risk polymorphisms in ESR2 gene are not necessarily inherited together as a haplotype. 
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Combined analysis of the SNP rs2987983 and the (CA)n polymorphism shown that the combination C-L is 
over-represented in patients (p<0.01), while T-S is over-represented in controls (p<0.01). Furthermore, the 
OR in the presence of the two risk genotypes (C/C)–(L/L) (38 patients vs 20 controls) is of 1.93 (OR 95% CI 
1.1-3.2), P<0.01, when compared with any other genotype. To test if the risk effects of the SNP rs2987983 
and the (CA)n repeat polymorphism were independent from each other, we used logistic regression 
analysis. For both the rs2987983 SNP the (CA)n, the co-dominant model performed better than the other 
tested models. We therefore used co-dominant coding to compare the fit of models containing the 
rs2987983 SNP and the (CA)n polymorphism.  
 
Three models were tested, one with only rs2987983, one with only the CA microsatellite and one with both 
polymorphisms. The model containing only the (CA)n data had the lowest p-value (p<0.003), followed by 
the one with both polymorphisms (p<0.004), the worst fit was observed for the model containing only 
rs2987983 (p<0.03). The SNP rs2987983 is not independently associated when the CA microsatellite is 
included in the model (Table 5). The significance of a model containing rs2987983 and the (CA)n is 
significantly better (p<0.02) than the significance of a model only containing rs2987983, while a model 
containing the CA repeat is not improved significantly by adding the rs2987983 marker.  
 
The results suggest that the two polymorphisms are not independently associated; of the studied 
polymorphisms the primary risk factors for hypospadias in the ESR2 sequence is a longer length of the 
(CA)n polymorphism. 
 
IV. ANALYSIS OF SEQUENCE AND EXPRESSION OF ATF3 IN HYPOSPADIAS 
 
MUTATION SCREENING 
 
We started the study of the ATF3 gene by performing sequencing of its coding sequence in 93 unrelated 
boys with hypospadias. Both sporadic and familial cases, mild to severe phenotypes, and boys from 
different ethnical groups were included. Several genetic variants were found in this screening.  
 
A missense mutation in exon 3, c.536A>G, causing an aminoacid substitution, Arg90Gly, was found in one 
Swedish boy with a sporadic, moderate to severe form of hypospadias. An 3’UTR gene variant, c.817C>T, 
was found in 2 unrelated patients, one Swedish patient with a sporadic form of hypospadias, and one boy 
from Middle East with a familiar form, both moderate to severe phenotypes. These gene variants were not 
found in the control population.  
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Homology analysis of the ATF3 mRNA revealed that the 536A>G gene variant is located in a highly 
conserved locus. Furthermore, protein structure prediction suggests that this variant induces a change in 
the protein structure (Figure 9). These evidences indicate that the variant 536A>G is likely to have a 
pathogenic consequence. Analysis of the c817C>T locus has shown that is not conserved. However, is 
predicted to be a highly regulatory sequence (data not shown).  
 
  
Figure 9: Protein prediction to ATF3 and ATF3 carrying the mutations 536A>G (ATF3 mut). Structure prediction: ATF3 
(Estimated precision: 95%) and ATF3mut (Estimated precision: 95%). Predicted at Protein Homology/analogY 
Recognition Engine/ Structural Bioinformatics Group Imperial College London. 
 
 
A new polymorphism was found in the promoter region, g.210848306delC, in heterozygous form in 7 out of 
93 patients and 8 out of 96 controls, indicating a frequency of the rarer allele of 4% in our population. This 
polymorphism is not associated to hypospadias (p=0.3).  
 
GENOTYPING 
 
To investigate further involvement of ATF3 in hypospadias, DNA from 354 boys with non-syndromic 
hypospadias and 380 healthy voluntary blood donors was genotyping for 8 haplotype tagging SNPs.  
 
All loci were in HWE. Single locus analysis of patients and controls revealed that four of the studied 
polymorphisms in ATF3 were preliminarily associated with an increased risk to hypospadias: The T allele in 
rs3125289, the T allele in rs1877474, the C allele in the rs11119982 and the C allele in the rs10735510 are 
associated with an increased risk to hypospadias. The estimated p-value after correction for multiple 
comparisons with 1000 permutations remained below 0.05 only for rs1877474 and rs11119982 (Tables 3 
and 4).  
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rs2137424 Controls Patients SUM  rs10735510 Controls Patients SUM 
CC 166 134 300  CC 127 91 218 
CT 152 124 276  CA 179 158 337 
TT 47 34 81  AA 68 75 143 
SUM 365 292 657  SUM 374 324 698 
P= 0.89 
   
P= 0.08 
  
rs3125289 Controls Patients SUM 
 
rs9429889 Controls Patients SUM 
CC 83 77 160  CC 285 235 520 
CT 189 113 302  CT 86 90 176 
TT 101 53 154  TT 6 10 16 
SUM 373 243 616  SUM 377 335 712 
P= 0.001    P= 0.07   
rs1877474 Controls Patients SUM 
 
rs12070345 Controls Patients SUM 
CC 122 134 256  AA 115 85 200 
CT 171 157 328  AG 174 170 344 
TT 81 46 127  GG 75 79 154 
SUM 374 337 711  SUM 364 334 698 
P= 0.003    P= 0.04   
rs11119982 Controls Patients SUM 
 
rs10475 Controls Patients SUM 
CC 146 88 234  CC 252 221 473 
CT 168 160 328  CT 116 96 212 
TT 61 81 142  TT 11 16 27 
SUM 375 329 704  SUM 379 333 712 
P= 0.0003    P= 0.18   
Table 3: Patients (P) vs. Controls (C) study for single locus analysis: Analysis of the genotypes for the 8 analyzed SNPs. 
SNPs rs3125289, rs1877474 and rs11119982 are associated with hypospadias, when genotype frequencies are 
individually analyzed. 
 
Study of haplotype effects, allowing for missing data such as uncertain phase and missing genotypes, has 
identified that the combination of the three risk alleles in the SNPs rs3125289 (T), rs1877474 (T) and 
rs11119982 (C) yield the higher effects; and the combination T-T-C is the more strongly associated with 
hypospadias in our study (P=4.6X10-14), suggesting a positive interaction of the three alleles in the risk to 
hypospadias. The estimated p-value after correcting for multiple comparisons by performing 1000 
permutations remains significant. Similarly, the allele combination C-C-T yields a significant p value as a 
protective haplotype. The D’, the normalized disequilibrium coefficient, is very low (0.06) evidencing that 
the alleles are not in LD. Other marker combinations were not statistically significant.  
 
Table 4: Patients (P) vs. Controls (C) study for single locus analysis: Four of the studied polymorphisms in ATF3 are 
associated with hypospadias: rs3125289, rs1877474, rs11119982, rs10735510. The estimated p-value after correcting 
for multiple comparisons by performing 1000 permutations* remains below 0.05 for rs1877474 and rs11119982.  
Permutation P-value calculated with Unphased and Haploview softwares allowing for missing data such as uncertain 
phase and missing genotypes. The 3 affected boys where the mutations 536A>G and c817C>T were found are 
heterozygous for the risk alleles in rs1877474 and in the rs11119982. 
 SNP1 
RS2137424 
SNP2 
RS3125289 
SNP3 
RS1877474 
SNP4 
 RS11119982 
SNP5 
RS10735510 
SNP6 
RS9429889 
SNP7 
RS12070345 
SNP8 
RS10475 
 
C>T C>T C>T C>T C>A C>T A>G C>T 
Cases 
Allele1 192 219 249 326 340 110 328 128 
% 33 45 37 49 52 84 49 19 
Allele2 392 267 425 336 308 560 340 538 
% 67 55 63 51 48 16 51 81 
Ctrls 
Allele1 246 391 333 290 427 98 324 138 
% 34 52 45 38.5 58 87 45 18 
Allele2 484 355 415 460 309 656 404 620 
% 66 48 55 61.5 42 13 55 82 
Case-
Ctrl 
study 
OR 
OR 95% CI 
0.96 
0.75-1.24 
0.74 
0.60-0.94 
0.73 
0.59-0.90 
1.54 
1.25-1.90 
0.8 
0.65-0.99 
1.2 
0.98-1.75 
1.2 
0.98-1.47 
1.07 
0.8-1.44 
p YATES 0.752 0.014 0.004 0.000 0.043 0.078 0.094 0.655 
Perm.P* NS NS 0.031 0.001 NS NS NS NS 
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Model fit Intercept only No interaction 
assumption 
Assumption of 
two-by-two 
interaction 
Assumption of all 
SNPs interacting  
AIC 811.989 782.056 775.322 770.718 
SC 816.393 799.671 788.533 779.526 
-2logL 809.989 774.056 769.322 766.718 
Likelihood ratio  35.9328 40.6668 43.2707 
p  7.7374E-08 1.47678E-09 4.76668E-11 
Table 5: Logistic regression modeling to evaluate the interaction between risk SNPs: rs3125289, rs1877474 and 
rs11119982, shows that there is an interaction between the three markers to cause susceptibility 
 
 
Logistic regression was performed to evaluate the apparently positive interaction between the three 
polymorphisms rs3125289, rs1877474 and rs11119982. The analysis revealed that the risk is higher if two 
susceptibility SNPs, rather than only one, are present. And the risk increases in the presence of an 
additional risk SNP, since the model that best fits is with the interaction term between all three markers; 
i.e. there is an interaction between the three markers to cause susceptibility. 
 
IMMUNOHISTOCHEMISTRY  
 
ATF3 PROTEIN EXPRESSION IN HUMAN PRE-PUBERTAL SAMPLES 
 
ATF3 protein expression is observed at the nuclei of stromal cells and the vascular endothelium in foreskin 
tissue samples from pre-pubertal boys with hypospadias and in healthy controls. The number of positive 
cells or the staining intensity did not differ notably between the patient group and the controls. In a few 
samples from patients and controls, some positively stained cells could be observed in the epidermal 
region. The ATF3 staining was then seen in both nuclei and cytoplasm in these cells of different origins 
(Figure 10) 
 
ATF3 PROTEIN EXPRESSION IN HUMAN FETAL SAMPLES 
 
Human fetal sections from gestational ages 9 to 15 weeks were analyzed for ATF3 expression by 
immunohistochemistry. ATF3 expression is seen in urethral wall at 15th weeks of gestation, but in earlier 
stages, particularly in the epithelium, localizing in the nucleus, preferentially located adjacent to the 
nuclear membrane (Figure 18). A similar pattern of expression was observed in the developing vagina, at 
every observed stage. Nuclear AFT3 expression was observed consistently in the rectum walls in both male 
and female fetuses  
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Figure10: ATF3 expression in human pre-pubertal genital skin from a boy with severe hypospadias (A and B), ATF3 
expression is observed in both dermal and in epidermal cells. The staining is mostly nuclear, but in certain epidermal 
cells of different origins ATF3 expression is localized in the cytoplasm (arrows). 
 
 
Figure 11: ATF3 expression in posterior urethra from fetal gestation week 15. ATF3 expression is seen in urethral wall, 
particularly in the epithelium, localizing in the nucleus preferentially located adjacent to the nuclear membrane; no 
expression was observed before the 15
th
 week. Similar expression pattern is seen in female vagina from 9
th
-15
th
 
gestational weeks. On the right, a similar section of the developing male urethra at 11 weeks shows no ATF3 immuno-
staining.   
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DISCUSSION  
 
The analyses of the selected candidate genes indicated sequence variants that may correlate with the risk 
to hypospadias. In this section, these findings are discussed.  
 
I. RARE GENE VARIANTS IN FGF8 AND FGFR2 ARE PRESENT IN BOYS WITH HYPOSPADIAS 
 
FGFs, BMPs and their receptors belong to a compact group of conserved “tool kit” genes, which take part in 
several developmental pathways, including the male urethra. Based on the studies of Fgf10, Fgfr2-IIIb and 
Hoxa13 knock-out mice, we analyzed the FGF10, FGFR2, FGF8 and BMP7 sequences in DNA from boys with 
hypospadias. Gene variants in FGF8 and FGFR2 were identified.  
 
The sequence variants on FGF8 were located around a region coding to the COOH-terminal of the protein. 
This region is shared by all the reported products of alternative splicing of this gene, which might be of 
importance to the protein function. However, none of these gene variants alter the predicted protein 
structure. The sequence variants in FGFR2 are more spread, and their functional consequences even more 
difficult to predict. The only non-synonymous variant (p.Met186Thr) does not have any predicted 
functional consequence. It is possible that these sequence variants might influence splicing or alter the 
structural folds of mRNA, or be in LD with functional regulatory mutations or polymorphisms. Or maybe, 
they are of no importance at all.  
 
FGF8 is induced by androgens through an AR mediated mechanism. This regulation acts through its 
Androgen Response Element sequences in its promoter (Payson RA et al, 1996; Gnanapragasam VJ et al, 
2002). Fgfr2-IIIb mediates the closure of the urethral tube through an androgen dependent process. The 
antagonism of AR leads to down-regulation of Fgfr2-IIIb in mouse genitalia. The presence of an AR binding 
site in the Fgfr2 promoter also supports an interaction between the two receptors (Petiot A et al, 2005). 
Since male genital development is an androgen dependent process (Ray R et al, 1998), the gene variants 
found in the FGF8 and FGFR2 genes of boys with hypospadias might interfere with androgen responses 
during the sexual dimorphic period of the urethral development. 
 
These findings suggest that gene variants in FGF8 and FGFR2 may influence the risk to this hypospadias. The 
analysis of non coding SNPs and haplotypes of the four genes with, as well as expression studies in human 
developing urethra are encouraged. 
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II. FKBP52 DOES NOT SEEM TO BE INVOLVED IN HYPOSPADIAS IN HUMANS 
 
Androgens, acting via the AR, have an essential role in the development of male genitalia (Rey R et al, 1998; 
Kim KS et al, 2002). Mutations in the AR are an uncommon occurrence in isolated hypospadias (Allera A et 
al, 1995, Sutherland RW et al, 1996). On the other hand, the complexity of AR regulation opens a highly 
unexplored area in the research in hypospadias and other undervirilisation phenotypes (Adachi M et al, 
2000; Hughes IA, 2000; New MI et al 1999).  
 
Our results indicate that FKBP52, a co-regulator of the AR, which plays a critical role in the murine male 
genital development (Cheung-Flynn J et al, 2005; Yong W et al, 2006), is expressed in genital skin of 
prepubertal boys. However, no obvious difference in the FKBP52 expression was observed between 
hypospadias patients and controls. Furthermore, the analysis of the FKBP4 sequence did not reveal any 
mutations or associated polymorphism. In spite of the phenotype of the fkbp52 null mice, and the high 
homology (89%) between human and mice proteins, with conserved functional domains, our results do not 
indicate alterations on the human FKBP4 coding sequence and expression in boys with non syndromic 
hypospadias.  
 
Differences in the regulation of the androgen pathway in human and mice have previously been described. 
It has been observed that the disruption of the Srd5a in mice does not induce any abnormal reproductive 
phenotype, while in humans, the presence of less active gene variants in its orthologue, SRD5A2, has been 
associated to hypospadias (Sutherland RW et al), infertility (Elzanaty S et al, 2006) and to various degrees of 
androgen insensitivity (Wilson JD et al, 1993) in men. Similarly, FKBP52 may be less important for full 
virilization of the male external genitalia in humans than its orthologue fkbp52 is in mice. The amplification 
of the androgen activity is required for proper male external genital development in the two species. And it 
is plausible that this is accomplished in humans mainly by the conversion of testosterone to DHT by 
SRD5A2; while the FKBP52-mediated AR transactivation plays a more crucial role in mice. Indeed, the fine 
regulation of gene expression is less well conserved between species then hormones and hormonal 
receptors sequences (Brigandt I, 2003). Another possibility is that mutations in FKBP4 in humans result in 
other undermasculinization phenotypes, which have not been the target of our study. 
 
This report indicates that alterations in the sequence and in the expression of the FKBP4 gene are not a 
common cause of non-syndromic hypospadias. Furthermore it highlights the risk of extrapolating from an 
animal model to humans, despite the undeniable usefulness of model organisms. The risk is higher when it 
concerns the fine regulation of hormonal signaling, which may be species specific. 
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III. GENE VARIANTS IN ESR2 INFLUENCE THE RISK TO HYPOSPADIAS  
 
Hypospadias has multifactorial etiology that involves the actions of environmental factors and endocrine-
active compounds against a genetic background. The role of estrogen in the development of hypospadias 
(Crescioli C et al, 2003; Dietrich W et al, 2004; Kim KS et al; 2004; Shapiro E et al, 2006; Yucel S et al, 2003) 
and the up-regulation of estrogen-responsive genes in hypospadiac tissue (Wang Z et al, 2007), led us to 
analyze the ESR genes in hypospadias. Our studies indicated that sequence variants in the ESR2 gene affect 
the risk to hypospadias.  
 
The gene variant c.2681-4 A>G in ESR2 was found in boys with hypospadias more frequently than in 
controls. This SNP is located close to the region that codes to the C-terminal fragment domain of the ESR2 
receptor, a region involved in the transactivation of the receptor. The C-terminal region seems to impair 
the binding of ESR2 to 17-beta-estradiol, while the removal of this region increases ESR2’s binding ability 
(Huang J et al, 2005). Furthermore, this gene variant is located close to a splicing site. Therefore, a potential 
functional implication could be theorized. However, splicing prediction analysis did not indicate any splicing 
change (data not shown). Moreover, further studies on ESR2, by typing tagging SNPs in a larger cohort, did 
not confirm association to this region of the gene. 
 
With regards to the (CA)n, it is known that intronic microsatellite repeats may lead to altered gene 
transcription, mRNA splicing, export to cytoplasm, induce heterochromatin- mediated- like gene silencing, 
or interactions with co-regulators (Li YC et al, 2004). This polymorphism has previously been associated 
with several conditions, such as with bone mineral density in postmenopausal women, endometrial cancer 
and systemic blood pressure (Scariano JK et al, 2004; Lau HH et al, 2002; Ogawa S et al, 2000; Setiawan VW 
et al, 2004; Ogawa S et al, 2000), which substantiates putative functional implications. Moreover, longer 
prolonged (CA)n variants are associated to lower levels of testosterone in a population-based cohort 
(Westberg et al, 2001). Lower levels of testosterone could then induce hypospadias in boys with longer 
(CA)n lengths. 
 
Association was also found with promoter gene variants, mapping to the SNP rs2987983, possibly affecting 
transcription factor binding. Promoter polymorphisms have previously been associated with the risk for 
several diseases (Setiawan VW et al, 2004; Ogawa S et al, 2000). And this aspect may be of particular 
relevance in ESR2, a steroid receptor, subjected to a complex regulation by co-regulators and general 
transcription factors, which modulate ESR2-target gene expression. Moreover, the SNP rs2987983 has 
previously been associated with prostate cancer risk in a Swedish cohort, corroborating with a possible 
functional consequence of this variant in the male reproductive tract (Thellenberg-Karlsson C et al, 2006).  
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The combination of the two risk polymorphisms – the C allele in rs2987983 and longer (CA)n variants - is 
also over represented in patients. These two polymorphisms are not necessarily inherited together as a 
haplotype, as demonstrated by a low LD. But when together, their effects are not independent, as indicated 
by the regression analysis, with the (CA)n polymorphism as the primary risk factor for hypospadias.  
 
Several mechanisms could explain how polymorphisms in ESR2, the predominant ESR in the developing 
male urethra (Dietrich W et al, 2004; Shapiro E et al, 2006), may influence the risk to hypospadias. One of 
such mechanisms is the interference with the balance between the effects produced by estrogens and 
androgens, as discussed before. Not only do estrogens modulate the levels of, and the responsiveness to, 
androgens; but also ESRs and ARs, both ligand-dependent nuclear factors, interact both at DNA and protein 
level. At the DNA level, these receptors may compete for the same binding sites, or affect protein-DNA 
interactions. At the protein level, AR & ESR interact with each other through specific domains, affecting 
their transactivational properties; interactions may also happen by squelching effect, or by competition for 
common transcriptional factors or co-regulators (Aranda A et al, 2001; Dellovade TL et al, 1995; Panet-
Raymond V et al, 2000; Toppari J et al, 1996; Zhou Q et al, 2001; Zhu YS et al, 1997).  
 
Sequence variants of the ESR2 may also directly affect the male genital development (Crescioli C et al 2003; 
Gooren L, 1989; Westberg L et al, 2001). Sequence variants may interfere with some of the proposed 
functions of ESR2, such as its anti-proliferative action, regulation of apoptosis and control of antioxidant 
gene expression (Leung YK et al, 2006). Moreover, since direct interactions of estrogenic chemicals with the 
ESR2 have been documented (Kuiper GG et al, 1998), ESR2 variants could influence the susceptibility to the 
deleterious actions of endocrine disrupters, explaining the ethnic differences observed in the response to 
such agents (Giwercman A et al, 2006). 
 
IV. ATF3, AN HORMONE RESPONSIVE GENE, IS INVOLVED IN HYPOSPADIAS  
 
The evaluation of ATF3 as a candidate for hypospadias, denotes that sequence variants of this gene, which 
is expressed in the human developing male urethra, may be involved in the genetic risk for hypospadias in 
different ways: By the effect of three common, low risk, SNPs in the intron 1 of ATF3; or induced by less 
common variants, possibly with higher effect, such as the missense mutation c.536A>G in the exon 3 and 
c.817C>T in the 3’UTR. The mechanisms that explain how variants in the sequence of ATF3 affect the risk to 
hypospadias are not yet known; but some hypothesis can be suggested. 
 
ATF3 has recently been involved in the hypospadias, both in humans and in animal models (Willingham E & 
Baskin LS, 2007; Wang Z et al, 2007; Hai T et al, 1999; Liu B el al, 2006). In mice, its orthologue atf3 is up-
regulated during sexual differentiation (Liu B et al, 2006) and is estrogen responsive (Liu B et al, 2006). 
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Furthermore, the expression of ATF3 is up-regulated in human hypospadic tissue, in some reports (Wang Z 
et al, 2007; Liu B et al, 2005). The potential role of estrogens and ESRs in hypospadias (Crescioli C et 
al,2003; Shapiro E et al, 2006; Dietrich W et al; 2004; Yucel S et al, 2003; Kim KS et al; 2004), and the 
estrogen responsiveness of a gene that has been shown up-regulated in hypospadias, motivated the 
selection of ATF3 as a candidate gene to hypospadias. This also may explain how variants of this gene may 
affect urethral development. But other aspects of this gene should also be considered. 
 
ATF3 is a key immediate early gene induced by gonadotropin-releasing hormone (GnRH) (Xie J et al, 2005). 
GnRH is required for synthesis and secretion of luteinizing hormone (LH) and follicle stimulating hormone 
(FSH), essential signals in the establishment of primary and secondary sexual characteristics. Interestingly, 
LH and FSH response to GnRH is higher in boys with hypospadias than those in prepubertal control subjects 
(Nonomura K et al, 1984) and genetic variants of the LH and its receptor have been associated to disorders 
of the male reproductive tract (Pals-Rylaarsdam R et al, 2005; Kaleva M et al, 2005; Themmen AP et al, 
1996). Furthermore, ATF3 expression is up-regulated by the AR’s activation by both androgens and 
estrogens in prostate cancer cell lines. And the treatment of these cells with an anti-androgen decreases 
ATF3 levels and partially abrogated induction by androgen (Pelzer AE et al, 2006). These evidences are of 
interest, due to the importance of androgens in male development (Klonish T et al, 2004). 
 
Furthermore, ATF3 responds to a given signal in epithelial cells via the TGF-beta pathway (Valcourt U et al, 
2005; Kang Y et al, 2003). Interestingly, genes involved in the TGF-beta pathway are up-regulated during 
several stages of murine urethral tube development (Willingham E & Baskin LS, 2007), where it facilitates 
epithelial and mesenchymal differentiation (Valcourt U et al, 2005; Kang Y et al, 2003; Massague J et al, 
2005). Furthermore, it has been suggested that ATF3 may lie at the centre of interactions between the TGF-
beta signaling pathway, and steroid-hormone receptors. These aspects provide further elucidation for the 
involvement of ATF3 in hypospadias. 
 
In other contexts, ATF3 has been characterized as a cellular adaptive response gene: The expression of ATF3 
protein is normally at a steady state in quiescent cells; but can be rapidly induced to a high level in 
response to multiple stress signals, such as ischemia, inflammation, nutrient limitation, wounding and 
toxicity (Hai T et al, 1999; Hartman MG, 2001; Pan YX et al, 2007). ATF3 has also been related to cell fate 
and to p38 and p53 related pro-apoptotic events (Fan F et al, 2002; Lu D et al, 2007; Yan C et al, 2006). 
Furthermore, the ATF3deltaZip2 isoform sensitizes cells to apoptotic cell death in response to tumor 
necrosis factor-alpha (Hua B et al, 2006). The role of ATF3 in apoptosis and adaptive responses may shed 
light into the molecular basis of its involvement in hypospadias. 
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Indeed, the normal male genital tubercle development depends on hormonal action, epithelial-
mesenchymal interactions and a balance between cell proliferation and apoptosis (Morgan EA, et al, 2003). 
ATF3 seem to be involved in all these aspects. We hypothesize that the inappropriate regulation of ATF3, by 
variants in its gene sequence, or by any other mechanism, such as lower nutrient availability (Pan YX et al, 
2007)–a link to low birth weight? - might halter the seam fusion process of the developing urethra and 
result in a shorter urethra with a proximal opening.  
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CONCLUDING REMARKS 
 
 
Hypospadias is one of the most common inborn errors of development with complex and still elusive 
etiology. Genes and environmental factors are believed to influence the risk to this disorder of the male 
genital development. Currently, hypospadias is repaired surgically, which constitutes one of the most 
common surgeries performed in neonates.  
 
 
The molecular mechanisms involved in the development of external genitalia during fetal life seem to 
depend on a complex balance between early morphogenetic cell-cell interactions; and between sex steroid 
hormones and related pathways. These balances can be disturbed by the exposure to environmental 
endocrine disruptors. But due to know ethnical differences in the response to such exposures, genetic 
factors may play an important role.  
 
 
The projects that were included in this thesis evidenced the involvement of sequence variants in FGFR2, 
FGF8, ESR2 and ATF3, four hormonal responsive genes, in hypospadias. These reports do not only increased 
our understanding about the complex etiology of this inborn error of development, but also highlight the 
importance of hormonal cascades in genital development. Further functional analysis of the implicated 
genes, the analysis of other endocrine related genes and pathways, and gene-environment studies are 
strongly encouraged. 
 
 
The overall aim of this thesis was to gain an increased understanding of the pathogenesis of hypospadias. 
An additional benefit would be to shed light on key mechanisms in sex differentiation. Despite no 
immediate clinical application of the presented results, the importance of increased information to affected 
families must not be under rated. Furthermore, although surgery may remain the therapy of choice for 
hypospadias, a better knowledge of the hormonal and molecular mechanisms of GT development may be 
the basis for preventive strategies reducing the incidence of this common malformation. 
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